

Annual Report 2019/12

(Fiscal year ended 31st December, 2019)

Contents

Five-Year Summary	1
Message from the President	2
Operating Results and Financial Status	3
Consolidated Financial Statements	8
Corporate Information	75

Five-Year Summary

Consolidated

	Millions of yen					Thousands of U.S. dollars
	December 2019	March 2019	March 2018	March 2017	March 2016	December 2019
Net sales	288,187	350,270	353,432	353,217	338,437	2,630,403
Profit before income taxes	20,183	18,798	22,473	26,492	20,962	184,218
Profit attributable to owners of the parent	12,047	11,844	15,216	18,147	13,903	109,958
	Yen					
Per share of common stock:						
Profit *	185.31	180.02	231.34	276.20	212.00	1.69
Cash dividends	60.00	60.00	50.00	50.00	40.00	0.54
	Millions of yen					
Balance sheet data:						
Shareholders' equity	204,169	201,098	192,694	180,435	163,968	1,863,535
Total assets	343,812	348,452	341,024	324,118	274,974	3,138,116

* Diluted profit per share for the years ended 31st December, 2019, and 31st March, 2019, 2018 and 2017 has not been disclosed because no dilutive potential shares with dilutive effect existed for the years ended 31st December, 2019, and 31st March, 2019, 2018 and 2017, and no dilutive potential shares existed for the year ended 31st March, 2016.

* 'Partial Amendments to Accounting Standard for Tax Effect Accounting' (Accounting Standards Board of Japan ('ASBJ') Statement No. 28, revised on 16th February, 2018) has been applied from the beginning of the year ended 31st March, 2019. This accounting standard has been retrospectively applied to the summary financial information for the year ended 31st March, 2018.

* The revision of the purchase price allocation following the finalisation of the tentative accounting treatment related to business combination in the year ended 31st March, 2019 has been reflected to the summary financial information for the year ended 31st March, 2018.

* For the fiscal period ended 31st December, 2019, the period for consolidated accounting of the Company and its consolidated subsidiaries whose fiscal year end was on 31st March is the nine-month period from 1st April, 2019 until 31st December, 2019 following the change of the fiscal year end.

* Fractions of one million yen and thousands of U.S. dollars are rounded off.

Message from the President

The Company changed its fiscal year end from 31st March to 31st December upon the resolution of “Partial Amendment of Articles of Incorporation” at the 114th Annual Shareholders Meeting held on 25th June, 2019. As a result, the fiscal period ended 31st December, 2019, which is a transitional period, will be a nine-month period from 1st April, 2019 until 31st December, 2019. The period for consolidated accounting of the Company and its domestic subsidiaries whose fiscal year end was on 31st March is the nine-month period from 1st April, 2019 until 31st December, 2019. The period for consolidated accounting of overseas subsidiaries whose fiscal year end was on 31st December will be a twelve-month period from 1st January, 2019 until 31st December, 2019. For comparison between the previous consolidated fiscal year, the amount for the previous consolidated fiscal year is adjusted based on a consistent period with the current consolidated fiscal period, and the percentage of increase and decrease is based on the comparison with the adjusted amount for the previous consolidated fiscal period.

In the consolidated fiscal year under review, the Japanese economy remained on a gradual recovery trend, reflecting the improvement in employment and earnings conditions as well as the effects from various policies. Meanwhile, the future outlook remained uncertain due to concerns about the impact of trade friction on the world economy, uncertainty of overseas economies including the future outlook of the Chinese economy, and the effects of fluctuations in the financial and capital markets.

In light of this situation, our corporate group has proactively implemented various measures. These include enhancing our mainstay brands and focusing management resources on accelerating development of the health business and overseas business centered on communication with consumers.

Our Dairy and Food Ingredients Divisions posted decreased sales from the previous fiscal year. However, sales of our Confectioneries and Food Products, Ice Cream, Overseas Divisions and other segments including the health business increased from the previous fiscal year. Consequently, consolidated net sales amounted to ¥288,187 million, an increase of 1.2% from the ¥284,830 million total of the previous fiscal year.


Regarding earnings, our overall cost-to-sales ratio remained unchanged from the previous fiscal year due to the decrease in cost-to-sales ratio in Overseas Division despite the increase in the ratio of Confectioneries and Food Products, and Ice Cream Divisions. As for selling, general and administrative (SG&A) expenses, expenses related to improvement of internal infrastructure for enhancing our business base increased.

As a result, operating income amounted to ¥15,605 million, a decrease of ¥332 million from the previous fiscal year (¥15,938 million). Ordinary income was ¥17,002 million, a decrease of ¥1,429 million from the previous fiscal year (¥18,431 million) due to negative factors including the decrease in operating income and loss on foreign exchange, net. Profit attributable to owners of the parent was ¥12,047 million, an increase of ¥161 million from the previous fiscal year (¥11,886 million), due to positive factors including gain on sales of property, plant and equipment and gain on sales of investments in securities.

Although we expect increasing difficulties in our business environment, we will unite the efforts of all Group companies to improve performance and meet the expectations of our shareholders.

Your continuing support will be deeply appreciated.

April 2020



Katsuhisa Ezaki, President and CEO

1. Operating Results and Financial Position

(1) Operating Results

Results by segment

(Unit: millions of yen, %)

Segment	Net Sales			Operating Income		
	Consolidated fiscal year under review	vs. Previous consolidated fiscal year	YoY (%)	Consolidated fiscal year under review	vs. Previous consolidated fiscal year	YoY (%)
Confectioneries and Food Products	71,789	1,323	1.9	5,236	378	7.8
Ice Cream	73,353	2,305	3.2	6,209	(866)	(12.2)
Dairy	67,032	(2,649)	(3.8)	2,386	(245)	(9.3)
Food Ingredients	8,314	(161)	(1.9)	648	(149)	(18.7)
Overseas	53,200	1,796	3.5	1,260	(88)	(6.6)
Others	14,496	742	5.4	251	206	454.1
Adjusted amount	—	—	—	(388)	432	—
Total	288,187	3,357	1.2	15,605	(332)	(2.1)

Note: The adjusted amount in the above table includes the eliminated amount of intersegment transactions and company-wide expenses not allocated to any reporting segment. The company-wide expenses mainly include the selling, general and administrative (SG&A) expenses not allocated to any reporting segment.

[Confectioneries and Food Products Division]

In Japan, overall confectionery sales increased from the previous fiscal year. ‘Pocky,’ ‘Pretz,’ ‘GABA’ and ‘LIBERA’ sales increased from the previous fiscal year. As a result, divisional sales amounted to ¥71,789 million, a 1.9% increase from the previous fiscal year (¥70,465 million).

As for divisional profits, cost-to-sales ratio increased, but ratio of sales promotion expenses and advertising expenses decreased. As a result, operating income was ¥5,236 million, an increase of ¥378 million from the previous fiscal year (¥4,858 million).

[Ice Cream Division]

Sales of mainstay products, including ‘Ice-no-Mi’ and ‘Panapp’ increased from the previous fiscal year while sales of some products, including ‘Papico,’ decreased from the previous fiscal year. Sales in wholesale sales subsidiaries also increased from the previous fiscal year. As a result, divisional sales totaled ¥73,353 million, a 3.2% increase from the previous fiscal year (¥71,048 million).

As for divisional profits, due to the increase in cost-to-sales ratio, operating income was ¥6,209 million, a decrease of ¥866 million from the previous fiscal year (¥7,076 million).

[Dairy Division]

While ‘ICREO,’ ‘Torori Cream-On’ and ‘Putchin Pudding’ sales increased from the previous fiscal year, ‘Café au Lait’ and ‘BifiX Yogurt’ sales decreased from the previous fiscal year. As a result, divisional sales totaled ¥67,032 million, a decrease of 3.8% from the previous fiscal year (¥69,681 million).

As for divisional profits, gross profit decreased due to the decrease in sales. As a result, operating income was ¥2,386 million, a decrease of ¥245 million from the previous fiscal year (¥2,632 million).

[Food Ingredients Division]

While 'E-Starch' and 'Fine Chemical' sales increased from the previous fiscal year, 'A-glu' and 'Starch' sales decreased from the previous fiscal year. As a result, divisional sales were ¥8,314 million, a 1.9% decrease from the previous fiscal year (¥8,476 million).

As for divisional profits, there was an increase in the cost-to-sales ratio. As a result, operating income was ¥648 million, a decrease of ¥149 million from the previous fiscal year (¥798 million).

[Overseas Division]

Sales revenue of our subsidiaries in China, Indonesia, and the U.S. increased from the previous fiscal year. As a result, divisional sales were ¥53,200 million, a 3.5% increase over the previous fiscal year (¥51,403 million).

As for divisional profits, while increased sales contributed to factors including an increase in gross profit, selling, general and administrative (SG&A) expenses increased. As a result, operating income was ¥1,260 million, a decrease of ¥88 million from the previous fiscal year (¥1,348 million).

[Others]

Sales of health food products such as 'Almond Koka' and 'SUNAO' increased from the previous fiscal year. As a result, sales in this segment totaled ¥14,496 million, a 5.4% increase over the previous fiscal year (¥13,754 million).

As for profits, the increase in gross profit generated from increased sales resulted in an increase of operating income to ¥251 million, an increase of ¥206 million over the previous fiscal year (¥45 million).

(2) Financial Position

Assets

As of 31st December, 2019, current assets were ¥184,352 million, an increase of ¥4,181 million from the end of the previous fiscal year. The main components of this increase were a ¥3,660 million increase in notes and accounts receivable, trade and a ¥4,322 million increase in marketable securities despite a ¥2,175 million decrease in finished goods and commercial goods. Non-current assets were ¥159,460 million, a decrease of ¥8,820 million from the end of the previous fiscal year. The main components of this decrease were a ¥6,497 million decrease in investments in securities and a ¥3,384 million decrease in goodwill as a result of the impairment. Consequently, total assets were ¥343,812 million, a decrease of ¥4,639 million compared to the end of the previous fiscal year.

Liabilities

As of 31st December, 2019, current liabilities were ¥80,689 million, a decrease of ¥1,059 million from the end of the previous fiscal year. The main components of this decrease were a ¥3,623 million decrease in other current liabilities and a ¥1,715 million decrease in accrued expenses despite a ¥2,189 million increase in notes and accounts payable, trade and a ¥1,615 million increase in income taxes payable. Long-term liabilities were ¥42,207 million, a decrease of ¥3,641 million from the end of the previous fiscal year. The main component of this decrease was a ¥2,454 million decrease in liability for retirement benefits. Consequently, total liabilities were ¥122,897 million, a decrease of ¥4,701 million compared to the end of the previous fiscal year.

Net Assets

As of 31st December, 2019, net assets were ¥220,915 million, an increase of ¥61 million compared to the end of the previous fiscal year. Main contributors to this increase included a profit attributable to owners of the parent amounting to ¥12,047 million offset by ¥4,253 million in cash dividends, a ¥3,716 million decrease in net unrealised holding loss on securities, a ¥2,378 million decrease in treasury stock and a ¥349 million decrease in translation adjustments. Consequently, shareholders' equity ratio was 62.0%, up 0.6 percentage points from the end of the previous fiscal year.

(3) Cash flows

(Unit: millions of yen)

	Previous consolidated fiscal year	Consolidated fiscal year under review	Increase (Decrease)
Cash flows from operating activities	20,324	17,344	–
Cash flows from investing activities	(8,697)	(9,022)	–
Cash flows from financing activities	(4,566)	(9,616)	–
Balance of cash and cash equivalents at beginning of current period	93,017	99,237	6,219
Balance of cash and cash equivalents at end of current period	99,237	98,005	(1,231)

As of 31st December, 2019, cash and cash equivalents totaled ¥98,005 million, a decrease of ¥1,231 million compared to the end of the previous fiscal year. The main reason for this decrease was because net cash used in investing activities and financing activities exceeded net cash provided by operating activities.

The consolidated fiscal year under review is the nine-month period from 1st April, 2019 until 31st December, 2019 due to the change of the fiscal year end.

Therefore, the percentages indicating year-on-year changes are not presented. Cash flows and reasons for changes during the consolidated fiscal year under review are as follows:

Cash flows from operating activities

Net cash provided by operating activities totaled ¥17,344 million. The main components of cash inflows included profit before income taxes amounting to ¥20,183 million recorded during the fiscal year under review, and depreciation and amortisation of ¥10,845 million, while cash outflows occurred mainly with income taxes paid amounting to ¥5,506 million.

Cash flows from investing activities

Net cash used in investing activities totaled ¥9,022 million. The main component of cash outflow was ¥16,274 million spent for purchases of property, plant and equipment, partially offset by cash inflow from proceeds from sales and redemption of investments in securities amounting to ¥9,951 million.

Cash flows from financing activities

Net cash used in financing activities totaled ¥9,616 million. The main components of cash outflows included ¥4,253 million spent for cash dividends paid and acquisition of treasury stock amounting to ¥5,002 million.

Reference: Cash flow indicator trends

	Mar. 2018	Mar. 2019	Dec. 2019
Shareholders' equity ratio (%)	61.1	61.4	62.0
Shareholders' equity ratio on market value basis (%)	106.7	109.9	91.9
Debt-to-cash flow ratio	0.0	0.0	0.0
Interest coverage ratio (times)	616.6	607.7	1,501.4

Notes:

Shareholders' equity ratio: Shareholders' equity / Total assets

Shareholders' equity ratio on market value basis: Market capitalization / Total assets

Debt-to-cash flow ratio: Interest-bearing liabilities / Cash flows from operating activities

Interest coverage ratio: Cash flows from operating activities / Interest paid

* All indicator values shown above were calculated from financial results on a consolidated basis.

* Market capitalization was calculated by multiplying the closing stock price at the end of the fiscal year by the total number of shares issued and outstanding at the end of the fiscal year (after deducting treasury stock).

* Cash flows from operating activities in the consolidated cash flow statements are used for the above equation. Interest-bearing liabilities refer to all liabilities for which the Company pays interest from among those recorded in the consolidated balance sheet. The amount of interest paid recorded in the consolidated cash flow statement is also included.

(4) Outlook for the Next Fiscal Year

It is expected that the Japanese and the global economy will continuously show a gradual recovery trend, reflecting the improvement in employment and earnings conditions as well as the effects from various policies. Meanwhile, the future outlook remained uncertain due to the impact of trade friction, the effects of the novel coronavirus whose worldwide spread of infection has become a concern, uncertainty of overseas economies and the effects of fluctuations in the financial and capital markets.

In light of this situation, we aim to achieve net sales of ¥366,000 million in the next fiscal year (a twelve-month period from 1st January, 2020 until 31st December, 2020). Our profit targets are: an operating income of ¥18,000 million, ordinary income of ¥18,500 million and a profit attributable to owners of the parent of ¥12,500 million.

Divisional consolidated sales forecasts for the next fiscal year

Divisional sales projections are as follows: Confectioneries and Food Products Division sales of ¥97,000 million, Ice Cream Division sales of ¥91,200 million, Dairy Division sales of ¥83,700 million, Food Ingredients Division sales of ¥10,800 million, Overseas Division sales of ¥63,100 million and other segment sales of ¥20,200 million.

The consolidated fiscal year under review is the nine-month period from 1st April, 2019 until 31st December, 2019 due to the change of the fiscal year end. Therefore, the description about year-on-year changes comparing the outlook for the year ended 31st December, 2020 is omitted.

2. Basic Policy for Selection of Accounting Standards

As a basic policy for the time being, our corporate group will prepare our consolidated financial statements in accordance with Japanese accounting standards based on the consideration of the comparability between accounting periods and between entities. As for the application of the International Financial Reporting Standards (IFRS), we will handle the matter appropriately by taking into account the situations inside and outside of Japan.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Financial Statements

Nine months ended 31st December, 2019

Contents

Independent Auditor's Report	9
Consolidated Balance Sheet	10
Consolidated Statement of Income and Comprehensive Income.....	12
Consolidated Statement of Changes in Net Assets.....	14
Consolidated Statement of Cash Flows.....	16
Notes to Consolidated Financial Statements	18



Independent Auditor's Report

The Board of Directors
Ezaki Glico Co., Ltd.

We have audited the accompanying consolidated financial statements of Ezaki Glico Co., Ltd. and its consolidated subsidiaries, which comprise the consolidated balance sheet as at 31st December, 2019, and the consolidated statements of income and comprehensive income, changes in net assets, and cash flows for the nine months then ended and a summary of significant accounting policies and other explanatory information, all expressed in Japanese yen.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in Japan, and for designing and operating such internal control as management determines is necessary to enable the preparation and fair presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. The purpose of an audit of the consolidated financial statements is not to express an opinion on the effectiveness of the entity's internal control, but in making these risk assessments the auditor considers internal controls relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Ezaki Glico Co., Ltd. and its consolidated subsidiaries as at 31st December, 2019, and their consolidated financial performance and cash flows for the nine months then ended in conformity with accounting principles generally accepted in Japan.

Convenience Translation

We have reviewed the translation of these consolidated financial statements into U.S. dollars, presented for the convenience of readers, and, in our opinion, the accompanying consolidated financial statements have been properly translated on the basis described in Note 1.

Ernst & Young ShinNihon LLC

24th March, 2020
Osaka, Japan

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Balance Sheet

31st December, 2019

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars) (Note 1)</i>
Assets			
Current assets:			
Cash and deposits <i>(Notes 7 and 8)</i>	¥ 99,640	¥ 103,601	\$ 909,456
Marketable securities <i>(Notes 7, 8 and 10)</i>	5,968	1,645	54,472
Notes and accounts receivable, trade <i>(Note 8)</i>	43,788	40,128	399,671
Inventories <i>(Note 11)</i>	29,873	31,112	272,663
Other current assets	5,132	3,733	46,841
Less allowance for doubtful accounts	(50)	(50)	(456)
Total current assets	184,352	180,171	1,682,657
 Property, plant and equipment <i>(Notes 12, 13, 14, 18 and 24):</i>			
Land	15,259	15,584	139,275
Buildings and structures	80,573	73,062	735,423
Machinery and vehicles	123,428	118,992	1,126,579
Tools, furniture and fixtures	24,799	24,340	226,350
Leased assets	1,385	1,720	12,641
Construction in progress	3,774	12,421	34,446
	249,219	246,121	2,274,726
Less accumulated depreciation	(149,412)	(146,655)	(1,363,745)
Property, plant and equipment, net	99,807	99,465	910,980
 Investments and other assets:			
Investments in unconsolidated subsidiaries and affiliates <i>(Note 8)</i>	5,187	2,830	47,343
Investments in securities <i>(Notes 8 and 10)</i>	30,114	38,969	274,863
Long-term loans receivable	72	917	657
Deferred tax assets <i>(Notes 4 and 21)</i>	798	939	7,283
Asset for retirement benefits <i>(Note 16)</i>	1,901	1,336	17,351
Real estate for investment, net <i>(Note 23)</i>	12,240	12,296	111,719
Software	4,776	4,688	43,592
Goodwill <i>(Notes 13 and 24)</i>	489	3,874	4,463
Other assets	4,124	3,015	37,641
Less allowance for doubtful accounts	(53)	(53)	(483)
Total investments and other assets	59,652	68,815	544,468
Total assets <i>(Note 24)</i>	¥ 343,812	¥ 348,452	\$ 3,138,116

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars) (Note 1)</i>
Liabilities and Net Assets			
Current liabilities:			
Notes and accounts payable, trade (Note 8)	¥ 36,020	¥ 33,831	\$ 328,769
Short-term loans payable (Notes 8 and 15)	29	229	2,227
Current portion of long-term debt (Note 15)	474	445	2,364
Accrued expenses	28,413	30,128	259,337
Income taxes payable (Note 21)	4,266	2,651	38,937
Provision for bonuses of directors and audit and supervisory board members	36	38	328
Provision for sales promotion expenses	2,977	2,448	27,172
Provision for stock-based compensation	30	44	273
Provision for loss on guarantees	134	–	1,223
Other current liabilities (Note 16)	8,306	11,931	75,812
Total current liabilities	80,689	81,749	736,482
Long-term liabilities:			
Convertible bonds (Notes 8, 15 and 25)	30,087	30,103	274,616
Long-term debt (Notes 8 and 15)	319	654	2,911
Liability for retirement benefits (Note 16)	2,831	5,286	25,839
Deferred tax liabilities (Notes 4 and 21)	4,186	5,098	38,207
Other long-term liabilities (Note 16)	4,782	4,706	43,647
Total long-term liabilities	42,207	45,849	385,240
Net assets:			
Shareholders' equity (Note 17):			
Common stock:			
Authorised – 270,000,000 shares at 31st December, 2019 and 31st March, 2019			
Issued – 68,468,569 shares at 31st December, 2019 and 69,414,469 shares 31st March, 2019	7,773	7,773	70,947
Capital surplus	7,459	8,999	68,081
Retained earnings	197,881	190,892	1,806,142
Treasury stock – 3,557,196 shares at 31st December, 2019 and 3,602,394 shares 31st March, 2019	(8,944)	(6,566)	(81,635)
Total shareholders' equity	204,169	201,098	1,863,535
Accumulated other comprehensive income:			
Net unrealised holding gain on securities	8,835	12,551	80,640
Deferred gain on hedges	73	73	666
Translation adjustments	45	395	410
Retirement benefits liability adjustments	56	(225)	511
Total accumulated other comprehensive income	9,011	12,794	82,247
Non-controlling interests	7,733	6,960	70,582
Total net assets (Note 25)	220,915	220,853	2,016,383
Total liabilities and net assets	¥ 343,812	¥ 348,452	\$ 3,138,116

See accompanying notes to the consolidated financial statements.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Statement of Income and Comprehensive Income

Nine months ended 31st December, 2019

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars) (Note 1)</i>
Net sales <i>(Note 24)</i>	¥ 288,187	¥ 350,270	\$ 2,630,403
Cost of sales <i>(Note 11)</i>	150,127	184,167	1,370,271
Gross profit	138,060	166,103	1,260,131
Selling, general and administrative expenses <i>(Notes 19 and 20)</i>	122,454	149,357	1,117,688
Operating income <i>(Note 24)</i>	15,605	16,746	142,433
Other income (expenses):			
Interest and dividend income	1,155	1,274	10,542
Interest expense	(11)	(33)	(100)
Gain on sales of property, plant and equipment <i>(Note 12)</i>	1,621	379	14,795
Loss on impairment of fixed assets <i>(Notes 13 and 24)</i>	(3,249)	(307)	(29,654)
Business structure improvement expenses <i>(Note 14)</i>	(75)	(516)	(684)
Gain on sales of investments in securities <i>(Note 10)</i>	5,647	425	51,542
Rental income on real estate <i>(Note 23)</i>	602	757	5,494
Subsidy income	534	489	4,874
(Loss) gain on foreign exchange, net	(315)	176	(2,875)
Loss on termination of retirement benefit plans <i>(Note 16)</i>	—	(292)	—
Depreciation of inactive fixed assets	(211)	(265)	(1,925)
Provision for loss on guarantees	(134)	—	(1,223)
Donation	(113)	(71)	(1,031)
Special retirement payment <i>(Note 16)</i>	(18)	(85)	(164)
Loss on disposal of property, plant and equipment	(473)	(486)	(4,317)
Loss on devaluation of investments in securities <i>(Note 10)</i>	(650)	—	(5,932)
Other, net	270	608	2,464
Other income, net	4,577	2,052	41,776
Profit before income taxes	20,183	18,798	184,218
Income taxes <i>(Note 21)</i> :			
Current	6,909	5,911	63,061
Deferred	862	470	7,867
	7,771	6,381	70,929
Profit	12,411	12,417	113,280
Other comprehensive loss <i>(Note 22)</i> :			
Net unrealised holding loss on securities	(3,716)	(1,035)	(33,917)
Deferred gain on hedges	0	73	0
Translation adjustments	231	(1,435)	2,108
Retirement benefits liability adjustments	281	(314)	2,564
Share of other comprehensive loss of affiliates accounted for by the equity method	(153)	(184)	(1,396)
Total other comprehensive loss	(3,354)	(2,896)	(30,613)
Comprehensive income	¥ 9,057	¥ 9,520	\$ 82,667

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Statement of Income and Comprehensive Income (continued)

Nine months ended 31st December, 2019

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars) (Note 1)</i>
Profit attributable to:			
Owners of the parent <i>(Note 25)</i>	¥ 12,047	¥ 11,844	\$ 109,958
Non-controlling interests	364	572	3,322
Total	¥ 12,411	¥ 12,417	\$ 113,280
Comprehensive income attributable to:			
Owners of the parent	¥ 8,263	¥ 9,039	\$ 75,419
Non-controlling interests	793	481	7,238
Total	¥ 9,057	¥ 9,520	\$ 82,667

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Statement of Changes in Net Assets

Nine months ended 31st December, 2019

	Shareholders' equity						Accumulated other comprehensive income					
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity	Net unrealised holding gain on securities	Deferred gain on hedges	Translation adjustments	Retirement benefits liability adjustments	Total accumulated other comprehensive income	Non-controlling interests	Total net assets
	<i>(Millions of yen)</i>											
Balance at 1st April, 2018	¥ 7,773	¥ 9,095	¥ 182,627	¥ (6,802)	¥ 192,694	¥ 13,587	¥ –	¥ 1,922	¥ 91	¥ 15,600	¥ 6,493	¥ 214,788
Cash dividends	–	–	(3,623)	–	(3,623)	–	–	–	–	–	–	(3,623)
Profit attributable to owners of the parent	–	–	11,844	–	11,844	–	–	–	–	–	–	11,844
Acquisition of treasury stock	–	–	–	(150)	(150)	–	–	–	–	–	–	(150)
Disposition of treasury stock	–	0	–	289	290	–	–	–	–	–	–	290
Cancellation of treasury stock	–	(97)	–	97	–	–	–	–	–	–	–	–
Change in scope of consolidation	–	–	43	–	43	–	–	–	–	–	–	43
Net changes in items other than those in shareholders' equity	–	–	–	–	–	(1,035)	73	(1,526)	(316)	(2,805)	466	(2,338)
Balance at 1st April, 2019	7,773	8,999	190,892	(6,566)	201,098	12,551	73	395	(225)	12,794	6,960	220,853
Cash dividends	–	–	(4,253)	–	(4,253)	–	–	–	–	–	–	(4,253)
Profit attributable to owners of the parent	–	–	12,047	–	12,047	–	–	–	–	–	–	12,047
Acquisition of treasury stock	–	–	–	(5,002)	(5,002)	–	–	–	–	–	–	(5,002)
Disposition of treasury stock	–	16	–	262	279	–	–	–	–	–	–	279
Cancellation of treasury stock	–	(1,556)	(805)	2,361	–	–	–	–	–	–	–	–
Net changes in items other than those in shareholders' equity	–	–	–	–	–	(3,716)	0	(349)	281	(3,783)	773	(3,009)
Balance at 31st December, 2019	¥ 7,773	¥ 7,459	¥ 197,881	¥ (8,944)	¥ 204,169	¥ 8,835	¥ 73	¥ 45	¥ 56	¥ 9,011	¥ 7,733	¥ 220,915

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Statement of Changes in Net Assets (continued)

Nine months ended 31st December, 2019

	Shareholders' equity					Accumulated other comprehensive income						Total net assets
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity	Net unrealised holding gain on securities	Deferred gain on hedges	Translation adjustments	Retirement benefits liability adjustments	Total accumulated other comprehensive income	Non-controlling interests	
						<i>(Thousands of U.S. dollars) (Note 1)</i>						
Balance at 1st April, 2019	\$ 70,947	\$ 82,137	\$ 1,742,351	\$ (59,930)	\$ 1,835,505	\$ 114,558	\$ 666	\$ 3,605	\$ (2,053)	\$ 116,776	\$ 63,526	\$2,015,817
Cash dividends	–	–	(38,818)	–	(38,818)	–	–	–	–	–	–	(38,818)
Profit attributable to owners of the parent	–	–	109,958	–	109,958	–	–	–	–	–	–	109,958
Acquisition of treasury stock	–	–	–	(45,655)	(45,655)	–	–	–	–	–	–	(45,655)
Disposition of treasury stock	–	146	–	2,391	2,546	–	–	–	–	–	–	2,546
Cancellation of treasury stock	–	(14,202)	(7,347)	21,549	–	–	–	–	–	–	–	–
Net changes in items other than those in shareholders' equity	–	–	–	–	–	(33,917)	0	(3,185)	2,564	(34,529)	7,055	(27,464)
Balance at 31st December, 2019	\$ 70,947	\$ 68,081	\$ 1,806,142	\$ (81,635)	\$ 1,863,535	\$ 80,640	\$ 666	\$ 410	\$ 511	\$ 82,247	\$ 70,582	\$2,016,383

See accompanying notes to the consolidated financial statements.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Statement of Cash Flows

Nine months ended 31st December, 2019

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars) (Note 1)</i>
Cash flows from operating activities:			
Profit before income taxes	¥ 20,183	¥ 18,798	\$ 184,218
Adjustments:			
Depreciation and amortisation	10,845	13,175	98,986
Loss on impairment of fixed assets	3,249	307	29,654
Net changes in asset and liability for retirement benefits	(2,614)	(1,298)	(23,859)
Decrease in provision for stock-based compensation of board incentive plan	—	(75)	—
Decrease in provision for bonuses of directors and audit and supervisory board members	(1)	—	(9)
(Decrease) increase in provision for stock-based compensation	(14)	44	(127)
Increase in provision for sales promotion expenses	528	561	4,819
Increase in provision for loss on guarantees	134	—	1,223
(Decrease) increase in allowance for doubtful accounts	(1)	24	(9)
Interest and dividend income	(1,155)	(1,274)	(10,542)
Interest expense	11	33	100
Loss (gain) on foreign exchange, net	211	(275)	1,925
Gain on sales of property, plant and equipment	(1,621)	(379)	(14,795)
Loss on disposal of property, plant and equipment	473	486	4,317
Gain on sales of investments in securities	(5,647)	(425)	(51,542)
Loss on valuation of investments in securities	650	—	5,932
(Increase) decrease in notes and accounts receivable, trade	(3,601)	903	(32,867)
Decrease (increase) in inventories	1,240	(3,761)	11,317
Increase in notes and accounts payable, trade	2,205	140	20,125
Other, net	(2,226)	(36)	(20,317)
Subtotal	22,851	26,950	208,570
Income taxes paid	(5,506)	(6,626)	(50,255)
Net cash provided by operating activities	17,344	20,324	158,305
Cash flows from investing activities:			
Increase in time deposits	(6,000)	(7,170)	(54,764)
Decrease in time deposits	7,000	13,970	63,891
Purchases of marketable securities	(2,500)	—	(22,818)
Proceeds from sales of marketable securities	—	600	—
Purchases of investments in securities	(4,458)	(1,355)	(40,690)
Proceeds from sales and redemption of investments in securities	9,951	1,104	90,826
Purchases of property, plant and equipment	(16,274)	(16,890)	(148,539)
Proceeds from sales of property, plant and equipment	2,837	930	25,894
Purchases of intangible assets	(2,104)	(1,587)	(19,204)
Proceeds from rental of real estate for investment	557	687	5,083
Increase in loans receivable	—	(5)	—
Collection of loans receivable	850	51	7,758
Interest and dividends received	1,180	1,354	10,770
Other, net	(62)	(386)	(565)
Net cash used in investing activities	(9,022)	(8,697)	(82,347)

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Consolidated Statement of Cash Flows (continued)

Nine months ended 31st December, 2019

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars) (Note 1)</i>
Cash flows from financing activities:			
Decrease in short-term loans payable, net	(189)	(496)	(1,725)
Repayment of long-term bank loans	(193)	(222)	(1,761)
Interest paid	(11)	(33)	(100)
Cash dividends paid	(4,253)	(3,623)	(38,818)
Cash dividends paid to non-controlling shareholders	(19)	(15)	(173)
Acquisition of treasury stock	(5,002)	(150)	(45,655)
Proceeds from sales of treasury stock	244	252	2,227
Other, net	(190)	(276)	(1,734)
Net cash used in financing activities	(9,616)	(4,566)	(87,769)
Effect of exchange rate changes on cash and cash equivalents	62	(840)	565
Net (decrease) increase in cash and cash equivalents	(1,231)	6,219	(11,235)
Cash and cash equivalents at beginning of the period	99,237	93,017	905,777
Cash and cash equivalents at end of the period <i>(Note 7)</i>	<u>¥ 98,005</u>	<u>¥ 99,237</u>	<u>\$ 894,532</u>

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements

31st December, 2019

1. Basis of Presentation

The accompanying consolidated financial statements of Ezaki Glico Co., Ltd. (the “Company”) and its consolidated subsidiaries (collectively, the “Group”) are prepared on the basis of accounting principles generally accepted in Japan (“Japanese GAAP”), which are different in certain respects as to the application and disclosure requirements of International Financial Reporting Standards (“IFRS”), and have been compiled from the consolidated financial statements prepared by the Company as required by the Financial Instruments and Exchange Law of Japan.

In preparing these consolidated financial statements, certain reclassifications and rearrangements have been made to the consolidated financial statements issued domestically in order to present them in a form which is more familiar to readers outside Japan. In addition, the notes to the accompanying consolidated financial statements include information which is not required under accounting principles generally accepted in Japan but is presented herein as additional information. Certain reclassifications of previously reported amounts have been made to conform the consolidated financial statements for the year ended 31st March, 2019 to the nine months ended 31st December, 2019 presentation. Such reclassification had no effect on consolidated profit.

Yen figures less than one million yen are rounded down to the nearest million yen and U.S. dollar figures less than one thousand dollars are rounded down to the nearest thousand dollars, except for per share data. As a result, the totals shown in the accompanying consolidated financial statements in yen and U.S. dollars do not necessarily agree with the sums of the individual amounts.

Amounts in U.S. dollars are included solely for the convenience of the reader. The rate of ¥109.56 = U.S. \$1.00, the approximate rate of exchange in effect on 31st December, 2019, has been utilised. The inclusion of such amounts is not intended to imply that yen amounts have been or could be readily converted, realised or settled in U.S. dollars at that or any other rate.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies

(a) Principles of consolidation and accounting for investments in unconsolidated subsidiaries and affiliates

The accompanying consolidated financial statements include the accounts of the Company and its 34 and 35 significant subsidiaries at 31st December, 2019 and 31st March, 2019, respectively.

Two subsidiaries are excluded from the scope of consolidation because the effect of their total assets, net sales, profit or loss, and retained earnings (each amount of profit or loss and retained earnings in proportion to the interest held by the Company) on the accompanying consolidated financial statements are not significant.

The number of affiliates accounted for by the equity method was 2 at 31st December, 2019 and 31st March, 2019, respectively.

Investments in two unconsolidated subsidiaries and an affiliate are not accounted for by the equity method but stated at cost, because the effect of their profit or loss and retained earnings (each amount in proportion to the interest held by the Company) on the accompanying consolidated financial statements are not significant individually or in the aggregate.

From the current fiscal period, the Company and its consolidated subsidiaries whose fiscal year end was 31st March changed their fiscal year end from 31st March to 31st December. These changes have been made with the expectation that by unifying the fiscal year end between the Company and overseas subsidiaries, the Company will be able to further promote the integrated operations of a global business and to increase the transparency of management by timely and appropriate disclosure of management information, as well as to align the fiscal year of the parent and its subsidiaries as required by IFRS, which the Company is considering to adopt in the future.

As a result of this change, in preparing the consolidated financial statements, the current fiscal period ended 31st December, 2019 is a transitional nine-month period from 1st April, 2019 to 31st December, 2019 for the Company and domestic subsidiaries whose fiscal year end was previously 31st March, as well as a twelve-month fiscal year from 1st January, 2019 to 31st December, 2019 for overseas subsidiaries whose fiscal year end is already 31st December.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (*continued*)

(a) *Principles of consolidation and accounting for investments in unconsolidated subsidiaries and affiliates (continued)*

The operating results from 1st January, 2019 until 31st March 2019 for the overseas subsidiaries whose fiscal year end is already 31st December were adjusted on the consolidated statement of income and comprehensive income. For the corresponding period, the adjusted amount of net sales was ¥13,081 million (\$119,395 thousand), operating income was ¥682 million (\$6,224 thousand), profit before income taxes was ¥1,329 million (\$12,130 thousand), and the change in translation adjustments was ¥662 million (\$6,042 thousand).

(b) *Foreign currency translation*

Monetary assets and liabilities denominated in foreign currencies are translated into yen at the exchange rates in effect at the balance sheet date. Revenues and expenses denominated in foreign currencies are translated at the average exchange rate in effect during the period. The resulting exchange gains and losses are credited or charged to profit.

The revenue and expense accounts of the foreign subsidiaries are translated into yen at the average exchange rate in effect during the period. Except for the components of net assets excluding non-controlling interests, the balance sheet accounts are also translated into yen at the rates of exchange in effect at the balance sheet date. The components of net assets excluding non-controlling interests are translated at their historical exchange rates. Differences arising from the translation are presented as translation adjustments and non-controlling interests in the consolidated balance sheet.

(c) *Cash and cash equivalents*

For purposes of the consolidated statement of cash flows, cash and cash equivalents consist of cash on hand, bank deposits available for withdrawal on demand, and short-term investments which are readily convertible to cash subject to an insignificant risk of any changes in value and which were purchased with an original maturity of three months or less.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

(d) Allowance for doubtful accounts

The allowance for doubtful accounts is provided to cover possible losses on collection. With respect to normal accounts receivables, loan receivables and others, allowance for doubtful accounts is stated at an amount based on the actual rate of historical bad debts, and for certain doubtful receivable, the uncollectible amount has been individually estimated.

(e) Marketable securities and investments in securities

The accounting standard applicable to financial instruments requires that securities be classified into three categories: trading securities, held-to-maturity debt securities or other securities. Trading securities are carried at fair value, and gain or loss, both realised and unrealised, is credited or charged to profit. Held-to-maturity debt securities are carried at amortised cost. Marketable securities classified as other securities are carried at fair value with any changes in unrealised holding gain or loss, net of the applicable income taxes, reported as a separate component of net assets. Non-marketable securities classified as other securities are carried at cost. Cost of securities sold is principally determined by the moving average method. For hybrid financial instruments containing an embedded derivative that cannot be reliably identified and measured separately, the entire contract is measured at fair value.

(f) Inventories

Inventories are stated at the lower of cost, determined principally by the gross average method, or net realisable value.

(g) Property, plant and equipment and real estate for investment (except for leased assets)

Property, plant and equipment and real estate for investment are stated at cost. Depreciation is principally determined by the declining-balance method over the estimated useful lives of the respective assets, except for buildings (excluding structures attached to the buildings) acquired on or after 1st April, 1998 and facilities attached to the buildings as well as structures acquired on or after 1st April, 2016 to which the straight-line method is applied.

(h) Software (except for leased assets)

Expenditures relating to the cost of computer software intended for internal use are charged to profit as incurred, except if these are deemed to contribute to the generation of future income or cost savings. Such expenditures are capitalised and amortised by the straight-line method over an estimated useful life of five years.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

(i) Goodwill

Goodwill is amortised by the straight-line method principally over a period of five to ten years.

(j) Leased assets

Leased assets under finance lease contracts that do not transfer ownership to the lessee are depreciated to a residual value of nil by the straight-line method using the term of the contract as the useful life.

(k) Provision for bonuses of directors and audit and supervisory board members

Provision for bonuses of directors and audit and supervisory board members is provided at the estimated amount of bonuses to be paid to directors and audit and supervisory board members subsequent to the balance sheet date for services rendered in the current fiscal period.

(l) Provision for sales promotion expenses

Provision for sales promotion expenses is provided at the estimated amount of sales promotion expenses to be paid to customers subsequent to the balance sheet date, which is calculated based on historical experience and sales amounts due to each customer.

(m) Provision for stock-based compensation

Provision for stock-based compensation in accordance with the restricted stock unit plan is provided at the estimated stock-based compensation amounts based on the estimated points to be granted to eligible directors under stock-based compensation rule of the Company.

(n) Provision for loss on guarantees

Provision for loss on guarantees is provided at the estimated amount of loss in case there is remaining debt balance related to the trust assets at the termination of the Trust Type Employee Shareholding Incentive Plan.

(o) Research and development costs

Research and development costs are expensed as incurred.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

(p) Income taxes

Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax bases of the assets and liabilities and are measured using the enacted tax rates and laws which will be in effect when the differences are expected to reverse.

(q) Retirement benefits

Liability for retirement benefits has been provided at an amount calculated based on the retirement benefit obligation and the fair value of the pension plan assets as of the balance sheet date. The retirement benefit obligation is attributed to each period by the benefit formula method over the remaining years of service of the eligible employees.

Prior service cost is amortised in the period in which it is recognised by the straight-line method over a period of five years, which is within the average remaining years of service of the eligible employees.

Actuarial gain or loss is amortised from the following year in which the gain or loss is recognised by the straight-line method over a period of five years, which is within the average remaining years of service of the eligible employees.

Certain consolidated subsidiaries have calculated their retirement benefit obligation and retirement benefit expenses based on the amount which would be payable at the year-end if all eligible employees terminated their services voluntarily (the “simplified method”).

(r) Derivative financial instruments and hedging activities

The Group enters into derivative transactions to effectively hedge foreign exchange fluctuation risk, in accordance with the Company’s internal policies.

Hedging instruments are forward exchange contracts and hedged items are accounts payable denominated in foreign currencies and forecasted transactions denominated in foreign currencies related to the import of raw materials.

All derivatives are stated at fair value with any changes in fair value included in profit or loss for the period in which they arise, except for derivatives which qualify as hedges and meet the criteria for deferral hedge accounting under which unrealised gain or loss, net of the applicable income taxes, is deferred as a component of net assets.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

(r) *Derivative financial instruments and hedging activities (continued)*

Hedge effectiveness is evaluated by comparing the cumulative changes in cash flows or fair value of the hedging instruments and the hedged items.

(s) *Consumption taxes*

Transactions subject to consumption taxes are recorded at amounts exclusive of consumption taxes.

(t) *Adoption of consolidated tax return system*

The Company and certain wholly owned domestic subsidiaries adopt the consolidated tax return system of Japan.

(u) *Accounting standards issued but not yet effective*

“Accounting Standard for Revenue Recognition” (Accounting Standards Board of Japan (“ASBJ”) Statement No. 29, issued on 30th March, 2018)

“Implementation Guidance on Accounting Standard for Revenue Recognition” (ASBJ Guidance No. 30, issued on 30th March, 2018)

(1) Overview

The International Accounting Standards Board (“IASB”) and the Financial Accounting Standards Board (“FASB”) have jointly developed a comprehensive accounting standard for revenue recognition and issued “Revenue from Contracts with Customers” (IASB’s IFRS 15 and FASB’s Topic 606) in May 2014. Considering that IFRS 15 is effective from fiscal years beginning on or after 1st January, 2018 and Topic 606 is effective from fiscal years beginning after 15th December, 2017, the ASBJ developed a comprehensive accounting standard for revenue recognition and issued it together with the implementation guidance.

In developing accounting standards regarding revenue recognition, the basic policy of the ASBJ was to include the basic principles of IFRS 15 in the accounting standards from a viewpoint of comparability between financial statements, which is one of the benefits of being in conformity with IFRS 15. However, if there is any item that needs particular consideration in light of Japanese business practices, a substitute treatment may be employed to the extent that it does not impair the comparability.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

(2) Scheduled date of adoption

The Group expects to adopt the accounting standard and implementation guidance from the beginning of the fiscal year ending 31st December, 2022.

(3) Impact of adopting the accounting standard and implementation guidance

The Company is currently evaluating the impact of adopting the accounting standard and the implementation guidance on the consolidated financial statements.

3. Change in Accounting Policies

The revenue and expense accounts of the foreign subsidiaries had previously been translated into yen at the exchange rates in effect at the balance sheet date. However, effective from the current fiscal period, the Company has changed the conversion method and applied the average exchange rate in effect during the period to translate the revenue and expense accounts of the foreign subsidiaries into yen. This change has been made in order to mitigate the impacts on profit or loss for the period from temporary fluctuations of exchange rates as at the balance sheet date and to more appropriately reflect the operating results of the foreign subsidiaries, in consideration of growing significance of overseas sales and other factors related to the foreign subsidiaries following the acceleration of overseas development. As the effect of this change was immaterial, no adjustments have been made retrospectively.

4. Change in Presentation

Applying “Partial Amendments to Accounting Standard for Tax Effect Accounting”

Effective from the current fiscal period, the Group has applied “Partial Amendments to Accounting Standard for Tax Effect Accounting” (ASBJ Statement No. 28 issued on 16th February, 2018), and in accordance with paragraphs 3 to 5, under which disclosure requirements stated in the explanatory notes 8 (excluding total amounts of valuation allowance) and 9 of Accounting Standard for Tax Effect Accounting were revised, the Group discloses additional information in Note 21 “Income Tax” related to tax loss carryforwards. To reflect this change in presentation, the corresponding notes for the previous fiscal year have been disclosed.

As a result, ¥3,060 million in “Valuation allowance” as of 31st March, 2019 has been reclassified into “Valuation allowance for tax loss carryforwards” of ¥667 million and “Valuation allowance for total deductible temporary differences and others” of ¥2,393 million in the table in Note 21 “Income Taxes.”

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Additional Information

Trust Type Employee Shareholding Incentive Plan (E-Ship®)

The Company has introduced a Trust Type Employee Shareholding Incentive Plan (E-Ship®) for the purpose of granting incentives to employees to contribute to enhancing corporate value of the Company in the mid and long term. The Company applied “Practical Solution on Transactions on Delivering the Company’s Own Stock to Employees, etc. through Trusts” (ASBJ Practical Issues Task Force (“PITF”) No. 30, revised on 26th March, 2015).

The plan is an incentive plan that covers all employees participating in the Shareholding Association.

Under the plan, the Company, as the trustor, set up the Ezaki Glico Shareholding Association Trust (the “E-Ship Trust”) at a trust bank, as the trustee. The E-Ship Trust purchases the number of shares of the Company in advance that the Shareholding Association expects to purchase over the next five years and subsequently sells the shares to the Shareholding Association periodically.

At the end of the trust period, the E-Ship Trust’s retained earnings, the accumulated of net gain on sales of its shares of the Company, are to be distributed to all eligible employees in accordance with the E-Ship Trust agreement.

On the other hand, the Company will guarantee retained loss, any accumulation of net loss on sales of its shares and will pay off the amount of outstanding debt at the end of the trust period, as it shall guarantee the debt of the E-Ship Trust.

The shares of the Company held by the E-Ship Trust were accounted for as treasury stock under net assets. The assets, liabilities, income and expenses of the E-Ship Trust were consolidated in the accompanying consolidated financial statements.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Additional Information (continued)

Employee Shareholding Incentive Plan (E-Ship®) (continued)

The book value and number of treasury stock held by the E-Ship Trust at 31st December, 2019 and 31st March, 2019 were as follows:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Book value	¥ 103	¥ 348	\$ 940
	31st December, 2019	31st March, 2019	
	<i>(Thousands of shares)</i>		
Number of treasury stock	16	54	

The book value of bank loans of the E-Ship Trust recorded in the consolidated balance sheet as of 31st December, 2019 and 31st March, 2019 were as follows.

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Book value	¥ 215	¥ 409	\$ 1,962

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Additional Information (continued)

Establishment of a specified subsidiary

The Company resolved at the Board of Directors' meeting on 18th December, 2019 that Glico Asia Pacific Pte. Ltd., a wholly owned company (specified subsidiary) will establish a new subsidiary in Indonesia. This new subsidiary will be a second-tier subsidiary to the Company. The procedures for its establishment will be completed by the end of March 2020. This new subsidiary will qualify as a specified subsidiary since its capital amount is expected to be 10% or more of the Company's capital amount.

(1) Purpose of establishment

The establishment of PT Glico Indonesia Manufacturing aims to boost production capacity for ASEAN and potentially other regional markets, in light of business expansion in the ASEAN region.

(2) Details of new (second-tier) specified subsidiary

1) Corporate name	PT Glico Manufacturing Indonesia
2) Business description	Manufacturing confectionery products and sales of its own products
3) Representative	Hideaki Nagahisa
4) Location	South Jakarta city, Republic of Indonesia
5) Date of establishment	End of March 2020 (expected)
6) Capital amount	USD 50 million
7) Composition of major shareholders and shareholding ratio	100% owned by the Group (99.998% owned by Glico Asia Pacific Pte. Ltd., and 0.002% owned by the Company

(3) Method of investment

Glico Asia Pacific Pte. Ltd., a wholly owned subsidiary of the Company (a specified subsidiary), will establish a second-tier subsidiary in Indonesia. Glico Asia Pacific Pte. Ltd. and the Company will own 99.998% and 0.002%, respectively, of the subsidiary's shares.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Changes in Scope of Consolidation

Ezaki Glico Vietnam Co., Ltd. was newly established by the Company in the current fiscal period. As a result, the accounts of Ezaki Glico Vietnam Co., Ltd. were included in the scope of consolidation in preparing the consolidated financial statements for the nine months ended 31st December, 2019. The accounts of both Kyushu Glico Co., Ltd., which was liquidated in the current fiscal period, and the accounts of Shojikiyanyuuhon Co., Ltd., which was absorbed by a consolidated subsidiary of the Company, Kansai Frozen Distribution Co., Ltd., were excluded from the scope of consolidation for the nine months ended 31st December, 2019.

7. Cash and Cash Equivalents

The balances of cash and deposits in the consolidated balance sheet at 31st December, 2019 and 31st March, 2019 are reconciled to the balances of cash and cash equivalents as presented in the consolidated statement of cash flows for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Cash and deposits	¥ 99,640	¥ 103,601	\$ 909,456
Time deposits with original maturities in excess of three months included in cash and deposits	(5,000)	(6,000)	(45,637)
Short-term investments which mature within three months of the dates of acquisition included in marketable securities	3,365	1,635	30,713
Cash and cash equivalents	¥ 98,005	¥ 99,237	\$ 894,532

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Financial Instruments

Policy for financial instruments

The Group raises funds mainly through bank borrowings and bond issuances taking into consideration its capital investment plan and other long-term capital needs. The Group raises short-term working capital through bank borrowings. The Group manages cash surpluses through highly liquid financial instruments, low-risk financial instruments like bonds issued by issuers with high credit ratings and stocks of other companies with which the Group has business relationships. Derivative transactions are utilised to reduce the risks described below; however, the Group does not enter into derivatives for speculative trading purposes.

Types of financial instruments and related risk

Trade receivables such as notes and accounts receivable are exposed to credit risk of customers. Marketable securities and investments in securities consist of bonds other than held-to-maturity debt securities and stocks; and those securities are exposed to credit risk, market fluctuation risk and interest rate fluctuation risk.

Trade payables such as notes and accounts payable are mostly due within six months. Short-term loans payable are utilised for the purpose of business activities and long-term loans payable and corporate bonds raised mainly for the purpose of making capital expenditures. Variable interest rate debt is exposed to interest rate fluctuation risk.

As for derivative financial instruments, forward exchange contracts are utilised for the purpose of reducing foreign exchange fluctuation risk from transactions denominated in foreign currencies.

Risk management for financial instruments

(1) Monitoring of credit risk (the risk that customers or counterparties may default)

The Group manages the due dates of collection and the balances of trade receivables in accordance with the credit management internal rules of each component, and regularly monitors the status of customers to identify an early point and mitigate the risk of bad debt from customers having financial difficulties. In addition, the Group utilises business credit insurance for some trade receivables.

The Group only acquires marketable securities and investments in securities issued by companies with high credit ratings. Accordingly, the Group believes that the credit risk deriving from such securities is insignificant.

In addition, the Group deals with only highly rated financial institutions to reduce counterparty risk in conducting derivative transactions.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Financial Instruments (continued)

Risk management for financial instruments (continued)

- (2) Monitoring of market risk (the risks arising from fluctuations in foreign exchange rates or interest rates)

For marketable securities and investments in securities, the Group periodically reviews the fair values of such securities and the financial position or the ratings of the issuers. In addition, the Group regularly evaluates whether securities should be maintained taking into account their fair values and business relationships with the issuers. In conducting and managing derivative transactions, the division in charge of each derivative transaction follows the internal policies, which set forth the delegation of authority. The officer in charge periodically reports actual transaction data to the Board of Directors.

- (3) Monitoring of liquidity risk (the risk that the Company cannot meet its obligations on scheduled due dates)

The Company has introduced a cash management system for the Company and its main domestic subsidiaries. Based on the business plan of the Company and each subsidiary, the finance department prepares and updates its cash flow plans taking into consideration actual operating results.

Supplementary explanation of the fair value of financial instruments

The estimated fair value of financial instruments is based on their quoted market price, if available. When there is no quoted market price available, fair value is reasonably estimated. Since various assumptions and factors are reflected in estimating the fair value, different assumptions and factors could result in different fair value.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Financial Instruments (continued)

Estimated fair value of financial instruments

Carrying value of financial instruments on the consolidated balance sheet, estimated fair value and the differences between them at 31st December, 2019 and 31st March, 2019 are shown in the following table. The following table does not include financial instruments for which it is extremely difficult to determine the fair value.

	31st December, 2019		
	Carrying value	Estimated fair value	Difference
	<i>(Millions of yen)</i>		
Assets:			
Cash and deposits	¥ 99,640	¥ 99,640	¥ –
Notes and accounts receivable, trade	43,788	43,788	–
Marketable securities and investments in securities	31,014	31,014	–
Total assets	¥ 174,443	¥ 174,443	¥ –
Liabilities:			
Notes and accounts payable, trade	¥ 36,020	¥ 36,020	¥ –
Short-term loans payable	244	244	–
Convertible bonds	30,087	30,045	(42)
Total liabilities	¥ 66,352	¥ 66,310	¥ (42)
Derivative financial instruments (*)	¥ 106	¥ 106	¥ –

(*) Assets and liabilities arising from derivative financial instruments are shown at net value with the amount in parentheses representing net liability position.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Financial Instruments (continued)

	31st March, 2019		
	Carrying value	Estimated fair value	Difference
	<i>(Millions of yen)</i>		
Assets:			
Cash and deposits	¥ 103,601	¥ 103,601	¥ –
Notes and accounts receivable, trade	40,128	40,128	–
Marketable securities and investments in securities	39,216	39,216	–
Total assets	¥ 182,946	¥ 182,946	¥ –
Liabilities:			
Notes and accounts payable, trade	¥ 33,831	¥ 33,831	¥ –
Short-term loans payable	417	417	–
Convertible bonds	30,103	30,750	646
Long-term bank loans	220	220	(0)
Total liabilities	¥ 64,573	¥ 65,219	¥ 646
Derivative financial instruments (*)	¥ 105	¥ 105	¥ –

(*) Assets and liabilities arising from derivative financial instruments are shown at net value with the amount in parentheses representing net liability position.

	31st December, 2019		
	Carrying value	Estimated fair value	Difference
	<i>(Thousands of U.S. dollars)</i>		
Assets:			
Cash and deposits	\$ 909,456	\$ 909,456	\$ –
Notes and accounts receivable, trade	399,671	399,671	–
Marketable securities and investments in securities	283,077	283,077	–
Total assets	\$ 1,592,214	\$ 1,592,214	\$ –
Liabilities:			
Notes and accounts payable, trade	\$ 328,769	\$ 328,769	\$ –
Short-term loans payable	2,227	2,227	–
Convertible bonds	274,616	274,233	(383)
Total liabilities	\$ 605,622	\$ 605,239	\$ (383)
Derivative financial instruments (*)	\$ 967	\$ 967	\$ –

(*) Assets and liabilities arising from derivative financial instruments are shown at net value with the amount in parentheses representing net liability position.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Financial Instruments (continued)

The methods to determine the estimated fair value of financial instruments and details on securities and derivative financial instruments are as follows:

Assets:

Cash and deposits, and notes and accounts receivable, trade:

Because these items are settled in a short term, their carrying value approximates the fair value.

Marketable securities and investments in securities:

The fair value of stocks is based on quoted market prices. The fair value of debt securities is based on either quoted market prices or prices provided by the financial institutions. (Refer to Note 10 “Marketable Securities and Investments in Securities” for the information on securities by holding purposes).

Liabilities:

Notes and accounts payable, trade, short-term loans payable and current portion of long-term bank loans:

Because these items are settled in a short term, their carrying value approximates the fair value.

Convertible bonds:

The fair value of convertible bonds is determined based on quoted market prices.

Long-term bank loans:

The fair value of long-term bank loans is determined by discounting the sum of principal and interest by the interest rate expected to be applied if similar bank loan was newly financed.

Derivative financial instruments:

The fair value of derivative financial instruments is based on the prices provided by the financial institutions (Refer to Note 9 “Derivative Financial Instruments”).

Financial instruments for which it is extremely difficult to determine the fair value are shown in the following table. Because no quoted market price is available and it is extremely difficult to determine the fair value, the following financial instruments are not included in the above table.

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Unlisted stocks	¥ 10,256	¥ 4,229	\$ 93,610

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Financial Instruments (continued)

The redemption schedule at 31st December, 2019 for deposits, trade receivables and securities with maturity dates is summarised as follows:

31st December, 2019				
	Due in one year or less	Due after one year through five years	Due after five years through ten years	Due after ten years
	<i>(Millions of yen)</i>			
Deposits	¥ 99,571	¥ –	¥ –	¥ –
Notes and accounts receivable, trade	43,788	–	–	–
Marketable securities and investments in securities:				
Other securities	5,120	20	2,346	–
Total	¥ 148,480	¥ 20	¥ 2,346	¥ –

31st December, 2019				
	Due in one year or less	Due after one year through five years	Due after five years through ten years	Due after ten years
	<i>(Thousands of U.S. dollars)</i>			
Deposits	\$ 908,826	\$ –	\$ –	\$ –
Notes and accounts receivable, trade	399,671	–	–	–
Marketable securities and investments in securities:				
Other securities	46,732	182	21,412	–
Total	\$1,355,239	\$ 182	\$ 21,412	\$ –

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

9. Derivative Financial Instruments

Derivative financial instruments to which hedge accounting is applied for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are summarised as follows:

For the nine months ended 31st December, 2019

Method of hedge accounting	Type of derivative financial instruments	Primary hedged items	Contract amount (Millions of yen / Thousands of U.S. dollars)	Contract amount due after one year (Millions of yen)	Estimated fair value (Millions of yen / Thousands of U.S. dollars)
Deferred hedge accounting	Forward exchange contracts Buying U.S. dollars	Accounts payable	¥ 8,836 (\$ 80,649)	¥ –	¥ 106 (\$ 967)

The fair value of derivative financial instruments is determined based on the prices provided by the financial institutions.

For the year ended 31st March, 2019

Method of hedge accounting	Type of derivative financial instruments	Primary hedged items	Contract amount (Millions of yen)	Contract amount due after one year (Millions of yen)	Estimated fair value (Millions of yen)
Deferred hedge accounting	Forward exchange contracts Buying U.S. dollars	Accounts payable	¥ 8,954	¥ –	¥ 105

The fair value of derivative financial instruments is determined based on the prices provided by the financial institutions.

There were no derivative financial instruments to which hedge accounting is not applied for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Marketable Securities and Investments in Securities

Marketable securities classified as other securities at 31st December, 2019 and 31st March, 2019 are summarised as follows:

31st December, 2019			
	Carrying value	Acquisition cost	Difference
	<i>(Millions of yen)</i>		
Securities whose carrying value exceeds their acquisition cost:			
Stock	¥ 23,055	¥ 11,020	¥ 12,035
Bonds	—	—	—
Subtotal	23,055	11,020	12,035
Securities whose carrying value does not exceed their acquisition cost:			
Stock	2,093	2,132	(39)
Other	5,865	5,865	—
Subtotal	7,958	7,998	(39)
Total	¥ 31,014	¥ 19,018	¥ 11,996

31st March, 2019			
	Carrying value	Acquisition cost	Difference
	<i>(Millions of yen)</i>		
Securities whose carrying value exceeds their acquisition cost:			
Stock	¥ 33,444	¥ 15,277	¥ 18,166
Other	1,835	1,756	79
Subtotal	35,280	17,033	18,246
Securities whose carrying value does not exceed their acquisition cost:			
Stock	2,279	2,745	(465)
Other	1,656	1,658	(2)
Subtotal	3,936	4,403	(467)
Total	¥ 39,216	¥ 21,437	¥ 17,778

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Marketable Securities and Investments in Securities (continued)

	31st December, 2019		
	Carrying value	Acquisition cost	Difference
	<i>(Thousands of U.S. dollars)</i>		
Securities whose carrying value exceeds their acquisition cost:			
Stock	\$ 210,432	\$ 100,584	\$ 109,848
Bonds	—	—	—
Subtotal	210,432	100,584	109,848
Securities whose carrying value does not exceed their acquisition cost:			
Stock	19,103	19,459	(355)
Other	53,532	53,532	—
Subtotal	72,635	73,001	(355)
Total	\$ 283,077	\$ 173,585	\$ 109,492

The proceeds from sales and gross realised gain on securities classified as other securities for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are summarised as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Proceeds from sales:			
Stock	¥ 9,946	¥ 1,105	\$ 90,781
Bonds	—	600	—
Total	¥ 9,946	¥ 1,705	\$ 90,781
Gross realised gain:			
Stock	¥ 5,647	¥ 425	\$ 51,542
Bonds	—	—	—
Total	¥ 5,647	¥ 425	\$ 51,542

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Marketable Securities and Investments in Securities (continued)

The Company and its consolidated subsidiaries recognised ¥650 million (\$5,932 thousand) of loss on devaluation of investment in securities classified as other securities for the nine months ended 31st December, 2019.

There were no losses on devaluation of investments in securities for the year ended 31st March, 2019.

The Company and its consolidated subsidiaries recognise loss on devaluation of investment securities in cases where the fair value at the balance sheet date of a security declines by more than 50% from its carrying value. The Company and its consolidated subsidiaries also recognise loss on devaluation of investment securities by considering the recoverability of fair value and so forth when the fair value at the balance sheet date declines by more than 30% and less than 50% from its carrying value.

11. Inventories

Inventories at 31st December, 2019 and 31st March, 2019 consisted of the following:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Finished goods and commercial goods	¥ 14,061	¥ 16,237	\$ 128,340
Work in process	795	768	7,256
Raw materials and supplies	15,016	14,106	137,057
	¥ 29,873	¥ 31,112	\$ 272,663

Cost of sales included loss on devaluation of inventories of ¥223 million (\$2,035 thousand) and ¥266 million for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively.

12. Gain on Sales of Property, Plant and Equipment

The main component of gain on sales of property, plant and equipment for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 is summarised as below.

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Land, buildings and structures	¥ 1,621	¥ 358	\$ 14,795

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

13. Loss on Impairment of Fixed Assets

Property, plant and equipment are grouped based on each unit which has decision-making authority for investing activities. Idle assets are grouped individually.

As to the grouping method of assets, for business assets, loss on impairment is recognised and measured based on the smallest grouping of assets that generate cash flows that are essentially independent classified by business segment, and for idle assets, loss on impairment is recognised and measured based on each individual unit. For goodwill, loss on impairment is recognised and measured based on each company.

The Group recognised loss on impairment of ¥3,249 million (\$29,654 thousand) for the nine months ended 31st December, 2019 as follows:

- Ezaki Glico Headquarters
For idle assets at Ezaki Glico Headquarters not expected to be utilised following the reorganisation of the Tsukamoto district, the book value of such assets was written down to their recoverable amounts. Loss on impairment consisted of buildings and structures of ¥118 million (\$1,077 thousand) and machinery, vehicles and others of ¥15 million (\$136 thousand).
- Chiba Ice Cream Co., Ltd. and Others
For business assets and idle assets at Chiba Ice Cream Co., Ltd. and Others not expected to be utilised in the future, the book value of such assets was written down to their recoverable amounts. Loss on impairment consisted of buildings and structures of ¥8 million (\$73 thousand) and machinery, vehicles and others of ¥106 million (\$967 thousand). These recoverable amounts were measured at net realisable value. Net realisable value was measured at zero.
- Thailand (Bangkok City and Others)
For ice cream production equipment, sales equipment and others, the financial results were significantly lower than the initial business plan and accordingly, the book value of such assets was written down to their recoverable amounts. Loss on impairment consisted of machinery and vehicles of ¥10 million (\$91 thousand) and tools, furniture and fixtures of ¥73 million (\$666 thousand). The recoverable amounts of these assets were measured at value in use. Since the future cash flow is expected to be negative, the value in use was measured at memorandum value.
- TCHO Ventures, Inc.
For goodwill attributable to TCHO Ventures, Inc., the Company recognised impairment loss of ¥2,916 million (\$26,615 thousand), which was the entire amount of the unamortised balance, in other expenses in the consolidated statement of income and comprehensive income since the excess profitability initially assumed was no longer expected. The value in use was measured at zero.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

13. Loss on Impairment of Fixed Assets (continued)

The Group recognised loss on impairment of ¥307 million for the year ended 31st March, 2019 as follows:

- Kyushu Glico, Hiroshima Glico Dairy and Others
For business assets and idle assets not expected to be utilised in the future, the book value of such assets was written down to zero. Loss on impairment consisted of machinery of ¥39 million and others of ¥7 million.
- Ezaki Glico Headquarters
For idle assets at Ezaki Glico Headquarters not expected to be utilised following the reorganisation of the Tsukamoto district, the book value of such assets was written down to their recoverable amounts. Loss on impairment consisted of buildings and structures of ¥124 million.
- Thailand (Bangkok City and Others)
For ice cream production equipment, sales equipment and others, the financial results were significantly lower than the initial business plan and accordingly, the book value of such assets was written down to their recoverable amounts. Loss on impairment consisted of machinery and vehicles of ¥134 million and tools, furniture and fixtures of ¥1 million. The recoverable amounts of these assets were measured at value in use. Since the future cash flow is expected to be negative, the value in use was measured at memorandum value.

14. Business Structure Improvement Expenses

The Company recorded business structure improvement expenses of ¥75 million (\$684 thousand) and ¥516 million for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively, as the Company dissolved a production subsidiary, following the reorganisation and redeployment of domestic production facilities aiming at increasing operational efficiency. Business structure improvement expenses primarily consist of loss on sales of machinery and others for the nine months ended 31st December, 2019 and of loss on sales of machinery and various restructuring expenses for the year ended 31st March, 2019.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

15. Short-Term Loans Payable, Long-Term Debt and Convertible Bonds

Short-term loans payable principally represent bank loans of the consolidated subsidiary. The average interest rates on outstanding loans at 31st December, 2019 and 31st March, 2019 were 0.43% and 1.633%, respectively.

Long-term debt at 31st December, 2019 and 31st March, 2019 consisted of the following:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Unsecured bank loans at average interest rates of 0.099%, due within 2020	¥ 215	¥ 409	\$ 1,962
Lease obligations	579	690	5,284
	794	1,100	7,247
Less current portion	(474)	(445)	(1,962)
Long-term debt	¥ 319	¥ 654	\$ 2,911

The aggregate annual maturities of lease obligations subsequent to 31st December, 2019 are summarised below:

Year ending 31st December,	Bank loans		Lease obligations	
	<i>(Millions of yen)</i>	<i>(Thousands of U.S. dollars)</i>	<i>(Millions of yen)</i>	<i>(Thousands of U.S. dollars)</i>
2020	¥ 215	\$ 1,962	¥ 259	\$ 2,364
2021	—	—	206	1,880
2022	—	—	59	538
2023	—	—	37	337
2024	—	—	15	136
2025 and thereafter	—	—	0	0
	¥ —	\$ —	¥ 579	\$ 5,284

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

15. Short-Term Loans Payable, Long-Term Debt and Convertible Bonds (continued)

Convertible bonds at 31st December, 2019 and 31st March, 2019 consisted of the following:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Euro-Yen denominated zero coupon convertible bonds due 2024 (with stock acquisition rights)	¥ 30,087	¥ 30,103	\$ 274,616

The details of the above convertible bonds are as follows:

	Euro-Yen denominated convertible bonds due 2024
Class of shares to be issued	Common stock
Total issue price of stock acquisition rights	Nil
Initial conversion price	¥8,033.0 (\$73.32) per share
Total issue price	¥30,000 million (\$273,822 thousand)
Total issue price of shares issued upon the exercise of stock acquisition rights	—
Percentage of stock acquisition rights granted	100.0%
Exercise period	13th February, 2017 through 16th January, 2024

(Note) The conversion price of the convertible bonds was subject to adjustment as it met certain conditions for adjustment of conversion price; therefore, it was adjusted from ¥8,033.0 (\$73.32) to ¥8,000.7 (\$73.02) from 1st January, 2020.

The repayment schedule of convertible bonds due within five years subsequent to 31st December, 2019 is as follows:

Year ending 31st December,	Convertible bonds	
	<i>(Millions of yen)</i>	<i>(Thousands of U.S. dollars)</i>
2020	¥ —	\$ —
2021	—	—
2022	—	—
2023	—	—
2024	30,087	274,616
	¥ 30,087	\$ 274,616

16. Retirement Benefits

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

The Company and certain of its domestic consolidated subsidiaries (Glico Nutrition Co., Ltd., and Koei Jyoho System Kabushiki Kaisha) have defined benefit plans, i.e., corporate pension fund plans in addition to lump-sum payment plans. The other consolidated subsidiaries only have lump-sum payment plans as defined benefit plans. The Company and 16 domestic consolidated subsidiaries have defined contribution pension plans. One consolidated subsidiary participates in a multi-employer pension plan and recorded required contributions as retirement benefit expenses since the subsidiary's portion of pension assets held by this multi-employer pension plan cannot be reasonably calculated.

The retirement benefits trust has been set up for lump-sum payment plans for the nine months ended 31st December, 2019.

The changes in the retirement benefit obligation for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Beginning balance of retirement benefit obligation	¥ 21,081	¥ 22,443	\$ 192,415
Service cost	776	1,065	7,082
Interest cost	61	104	556
Actuarial loss	49	101	447
Benefits paid	(1,201)	(2,399)	(10,962)
Decrease due to transfer to defined contribution pension plans	—	(203)	—
Others	104	(30)	949
Ending balance of retirement benefit obligation	¥ 20,872	¥ 21,081	\$ 190,507

Retirement benefit obligation calculated by the simplified method is included in the above table.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

16. Retirement Benefits (continued)

The changes in plan assets at fair value for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Beginning balance of plan assets at fair value	¥ 17,131	¥ 17,647	\$ 156,361
Expected return on plan assets	332	440	3,030
Actuarial gain (loss)	409	(233)	3,733
Contributions by the employers	255	337	2,327
Contribution to retirement benefit trust	2,700	—	24,644
Retirement benefits paid	(886)	(1,045)	(8,086)
Others	(0)	(15)	(3)
Ending balance of plan assets at fair value	¥ 19,942	¥ 17,131	\$ 182,018

The Company has set up the retirement benefits trust from the current fiscal period.

The reconciliation of the ending balances of the retirement benefit obligation and plan assets to the asset and liability for retirement benefits recognised in the consolidated balance sheet at 31st December, 2019 and 31st March, 2019 is as follows:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Funded retirement benefit obligation	¥ 18,091	¥ 15,805	\$ 165,124
Plan assets at fair value	(19,942)	(17,131)	(182,018)
	(1,850)	(1,325)	(16,885)
Unfunded retirement benefit obligations	2,780	5,275	25,374
Net liability for retirement benefits	929	3,950	8,479
Liability for retirement benefits	2,831	5,286	25,839
Asset for retirement benefits	(1,901)	(1,336)	(17,351)
Net liability for retirement benefits	¥ 929	¥ 3,950	\$ 8,479

Retirement benefit obligation calculated by the simplified method is included in the above table.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

16. Retirement Benefits (continued)

The components of retirement benefit expenses for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Service cost	¥ 776	¥ 1,065	\$ 7,082
Interest cost	61	104	556
Expected return on plan assets	(332)	(440)	(3,030)
Amortisation:			
Actuarial loss (gain)	60	(89)	547
Prior service cost	(15)	(20)	(136)
Others	253	(14)	2,309
Retirement benefit expenses	¥ 804	¥ 604	\$ 7,338
Special retirement payment	¥ 18	¥ 85	\$ 164
Loss resulting from transfer to defined contribution pension plans	¥ –	¥ 292	\$ –

(Notes)

1. Retirement benefit expenses calculated by the simplified method are included in “Service cost” of the above table.
2. “Special retirement payment” is included in “Other expenses.”
3. “Loss resulting from transfer to defined contribution pension plans” is included in “Other expense” as “Loss on termination of retirement benefit plans.”

The components of retirement benefit liability adjustments included in other comprehensive loss (before tax effect) are as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Prior service cost	¥ (15)	¥ (20)	\$ (136)
Actuarial gain (loss)	421	(432)	3,842
Total	¥ 405	¥ (453)	\$ 3,696

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

16. Retirement Benefits (continued)

The components of retirement benefit liability adjustments included in accumulated other comprehensive income (before tax effect) are as follows:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Unrecognised prior service cost	¥ 36	¥ 51	\$ 328
Unrecognised actuarial gain (loss)	44	(377)	401
Total	¥ 80	¥ (325)	\$ 730

The fair value of plan assets, by major category, as a percentage of total plan assets as of 31st December, 2019 and 31st March, 2019 are as follows:

	31st December, 2019	31st March, 2019
Bonds	42%	40%
Equities	30	30
General accounts at life insurance companies	7	5
Other	21	25
Total	100%	100%

The total amount of plan assets include 13.6% of the retirement benefit trust for lump-sum payment plans for the current fiscal period.

The assumptions used in accounting for the above plans are as follows:

	31st December, 2019	31st March, 2019
Discount rates	0.0%~0.8%	0.0%~0.8%
Expected long-term rate of return on plan assets	2.5%	2.5%
Expected rates of future salary increase	7.4%~14.0%	7.4%~14.0%

The expected long-term rate of return on plan assets is determined as a result of consideration of both the portfolio allocation at present and in the future, and expected long-term rate of return from multiple plan assets at present and in the future.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

16. Retirement Benefits (continued)

The contributions to the multi-employer plan were ¥3 million (\$27 thousand) and ¥11 million for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively, and are accounted for in the same manner as contributions to the defined contribution plans. As the amount of the fund has not been finalised yet at this point, the status of the multi-employer pension plan, the contribution ratio of the consolidated subsidiaries to the multi-employer pension plan, and supplemental explanation for the current fiscal period are omitted.

The following table sets forth the status of the multi-employer pension plan as of 31st March, 2019.

	31st March, 2019
	<i>(Millions of yen)</i>
Plan assets	¥ 531,843
Total of amount of the pension obligation based on the calculation of pension financing in the scheme and minimum reserve amount	512,770
Difference	¥ 19,073

The contribution ratio of the consolidated subsidiaries to the multi-employer pension plan for the year ended 31st March, 2019 was 0.05%.

The main reasons behind the difference in the above table are due to unrecognised prior service cost of ¥23,254 million and net of surplus of ¥42,328 million as of 31st March, 2019. The contribution ratio noted outlined above does not equal to the subsidiary's actual share of the pension obligation.

The amount of plan assets transferred to the defined contribution pension plans as a result of the transfer of a portion of the lump-sum payment plans to the defined contribution pension plan was ¥3,629 million (\$33,123 thousand) and the transfer is expected to be completed in four years from the beginning of the transfer. The portion of plan assets yet to be transferred at 31st December, 2019 in the amount of ¥358 million (\$3,267 thousand) is included in accounts payable, other under "Other current liabilities" and long-term accounts payable, other under "Other long-term liabilities."

The amounts to be paid to the defined contribution plans by the Company and certain consolidated subsidiaries were ¥181 million (\$1,652 thousand) and ¥212 million for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

17. Shareholders' Equity

The Corporation Law of Japan provides that an amount equal to 10% of the amount to be disbursed as distributions of capital surplus (other than the capital reserve) and retained earnings (other than the legal reserve) be transferred to the capital reserve and the legal reserve, respectively, until the sum of the capital reserve and the legal reserve equals 25% of the common stock account. Such distributions can be made at any time by resolution of the shareholders or by the Board of Directors if certain conditions are met.

The legal reserve of the Company, which is included in retained earnings, amounted to ¥1,943 million (\$17,734 thousand) at 31st December, 2019 and 31st March, 2019, respectively.

Movements in issued shares of common stock and treasury stock during the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are summarised as follows:

For the nine months ended 31st December, 2019

	Number of Shares			
	Nine months ended 31st December, 2019			
	1st April, 2019	Increase	Decrease	31st December, 2019
Issued shares:				
Common stock	69,414,469	—	945,900	68,468,569
Treasury stock	3,602,394	946,577	991,775	3,557,196

The decrease in common stock of 945,900 shares was due to the cancellation of treasury stock.

The increase in treasury stock of 946,577 shares was due to the acquisition of treasury stock of 945,900 shares and the acquisition of fractional shares of less than one voting unit of 677 shares. The decrease in treasury stock of 991,775 shares was due to the sales of fractional shares of less than one voting unit of 75 shares, issuance of treasury stock through the E-Ship Trust of 38,600 shares, granting from the Restricted Stock Unit Plan to Directors of 7,200 shares and cancellation of treasury stock of 945,900 shares.

Treasury stock at 31st December, 2019 includes 16,300 shares held by the E-ship Trust.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

17. Shareholders' Equity (continued)

For the year ended 31st March, 2019

	Number of Shares			
	Year ended 31st March, 2019			
	1st April, 2018	Increase	Decrease	31st March, 2019
Issued shares:				
Common stock	69,430,069	—	15,600	69,414,469
Treasury stock	3,636,411	27,530	61,547	3,602,394

The decrease in common stock of 15,600 shares was due to the cancellation of treasury stock.

The increase in treasury stock of 27,530 shares was due to the acquisition of fractional shares of less than one voting unit. The decrease in treasury stock of 61,547 shares was due to the sales of fractional shares of less than one voting unit of 147 shares, issuance of treasury stock through the E-Ship Trust of 39,900 shares, shares granted from the BIP Trust to Directors of 5,900 shares and cancellation of treasury stock of 15,600 shares held by the BIP Trust as a result of termination of the BIP Trust.

Treasury stock at 31st March, 2019 includes 54,900 shares held by the E-ship Trust.

Information on stock acquisition rights and treasury stock acquisition rights during the nine months ended 31st December, 2019 and the year ended 31st March, 2019 is as follows:

For the nine months ended 31st December, 2019

Company name	Details	Type of stock subject to acquisition rights	Number of shares subject to stock acquisition rights			31st December, 2019 (Millions of yen / Thousands of U.S. dollars)
			1st April, 2019	Increase	Decrease	
The Company	Euro-Yen denominated zero coupon convertible bonds due 2024 (with stock acquisition rights)	Common stock	3,721,068	(Note 1) 13,526	—	3,734,594 (Note 2) —

- (Notes)
1. The increase in the Euro-Yen denominated zero coupon convertible bonds due 2024 (with stock acquisition rights) was due to the adjustment of the conversion price.
 2. Convertible bonds are accounted for using the lump-sum method, by which the bond portion and a stock acquisition right portion are treated as non-separable.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

17. Shareholders' Equity (continued)

For the year ended 31st March, 2019

Company name	Details	Type of stock subject to stock acquisition rights	Number of shares subject to stock acquisition rights			31st March, 2019	31st March, 2019 (Millions of yen)
			1st April, 2018	Increase	Decrease		
The Company	Euro-Yen denominated zero coupon convertible bonds due 2024 (with stock acquisition rights)	Common stock	3,713,882	(Note 1) 7,186	—	3,721,068	(Note 2) —

(Notes) 1. The increase in the Euro-Yen denominated zero coupon convertible bonds due 2024 (with stock acquisition rights) was due to the adjustment of the conversion price.

2. Convertible bonds are accounted for using the lump-sum method, by which the bond portion and a stock acquisition right portion are treated as non-separable.

Information on dividend payments and the effective date for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 is as follows:

For the nine months ended 31st December, 2019

Dividend payment:

Resolution	Type of shares	Dividends paid (Millions of yen/ Thousands of U.S. dollars)	Dividend per share (Yen/ U.S. dollars)	Record date	Effective date
Board of Directors' meeting held on 13th May, 2019	Common stock	¥ 2,305 (\$ 21,038)	¥ 35 (\$ 0.31)	31st March, 2019	6th June, 2019
Board of Directors' meeting held on 31st October, 2019	Common stock	¥ 1,947 (\$ 17,771)	¥ 30 (\$ 0.27)	30th September, 2019	6th December, 2019

The dividend payment pursuant to the resolution by the Board of Directors' meeting held on 13th May, 2019 included ¥1 million (\$9 thousand) of cash dividends applicable to shares held by the E-Ship Trust.

The dividend payment pursuant to the resolution by the Board of Directors' meeting held on 31st October, 2019 included ¥0 million (\$0 thousand) of cash dividends applicable to shares held by the E-Ship Trust.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

17. Shareholders' Equity (continued)

Dividend payment with an effective date in the following year:

Resolution	Type of shares	Dividends paid (Millions of yen/ Thousands of U.S. dollars)	Source of dividend	Dividend per share (Yen/ U.S. dollars)	Record date	Effective date
Board of Directors' meeting held on 14th February, 2020	Common stock	¥ 1,947 (\$ 17,771)	Retained earnings	¥ 30 (\$ 0.27)	31st December, 2019	6th March, 2020

The dividend payment pursuant to the resolution by the Board of Directors' meeting held on 14th February, 2020 included ¥0 million (\$0 thousand) of cash dividends applicable to shares held by the E-Ship Trust.

For the year ended 31st March, 2019

Dividend payment:

Resolution	Type of shares	Dividends paid (Millions of yen)	Dividend per share (Yen)	Record date	Effective date
Board of Directors' meeting held on 14th May, 2018	Common stock	¥ 1,977	¥ 30	31st March, 2018	6th June, 2018
Board of Directors' meeting held on 31st October, 2018	Common stock	¥ 1,646	¥ 25	30th September, 2018	10th December, 2018

The dividend payment pursuant to the resolution by the Board of Directors' meeting held on 14th May, 2018 included ¥3 million of cash dividends applicable to shares held by the E-Ship Trust and the BIP Trust.

The dividend payment pursuant to the resolution by the Board of Directors' meeting held on 31st October, 2018 included ¥1 million of cash dividends applicable to shares held by the E-Ship Trust.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

18. Leases

Leased assets under finance lease transactions which do not transfer ownership to the lessee mainly consist of tools, furniture and fixtures, vehicles and software.

As described in Note 2 “Summary of Significant Accounting Policies, (j) Leased assets,” leased assets under finance lease transactions which do not transfer ownership to the lessee are capitalised and depreciated to a residual value of nil by the straight-line method using the term of the contracts as the useful life.

Future minimum lease payments under non-cancellable operating leases subsequent to 31st December, 2019 for operating leases are summarised as follows:

Year ending 31st December,	(Millions of yen)	(Thousands of U.S. dollars)
2020	¥ 223	\$ 2,035
2021 and thereafter	54	492
Total	¥ 278	\$ 2,537

19. Selling, General and Administrative Expenses

The components of selling, general and administrative expenses for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 were as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	(Millions of yen)		(Thousands of U.S. dollars)
Freight and warehouse expenses	¥ 24,855	¥ 30,617	\$ 226,861
Sales promotion expenses	42,776	53,243	390,434
Provision for sales promotion expenses	2,977	2,448	27,172
Advertising expenses	11,717	14,408	106,945
Salaries	14,182	17,200	129,445
Bonuses	4,069	5,615	37,139
Welfare expenses	4,127	5,158	37,668
Retirement benefit expenses	723	492	6,599
(Reversal) provision of allowance for doubtful accounts	(0)	22	(0)
Provision for bonuses of directors and audit and supervisory board members	36	38	328
Provision for stock-based compensation	30	44	273
Depreciation and amortisation	2,354	2,635	21,485
Other	14,602	17,430	133,278
Total	¥ 122,454	¥ 149,357	\$ 1,117,688

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

20. Research and Development Expenses

Research and development expenses included in selling, general and administrative expenses for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 amounted to ¥4,071 million (\$37,157 thousand) and ¥5,520 million, respectively.

21. Income Taxes

The Company and its domestic consolidated subsidiaries are subject to several types of taxes: corporate taxes, local inhabitants taxes and enterprise taxes, which in aggregate resulted in a statutory tax rate of approximately 30.6% for the nine months ended 31st December, 2019 and the year ended 31st March, 2019. Overseas subsidiaries are subject to the income and other taxes of the respective countries in which they operate.

The reconciliation between effective tax rate and the statutory tax rate for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 is as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019
Statutory tax rate	30.6%	30.6%
Permanent non-deductible expenses	1.6	1.8
Permanent non-taxable dividend income	(0.4)	(0.7)
Inhabitants' per capita taxes	0.3	0.4
Change in valuation allowance	6.8	1.7
Tax credits	(0.6)	(1.5)
Other	0.2	1.7
Effective tax rate	38.5%	34.0%

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

21. Income Taxes (continued)

The significant components of deferred tax assets and liabilities of the Company and its consolidated subsidiaries at 31st December, 2019 and 31st March, 2019 are summarised as follows:

	31st December, 2019	31st March, 2019	31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Deferred tax assets:			
Accrued bonuses	¥ 587	¥ 964	\$ 5,357
Accrued expenses	1,212	1,029	11,062
Liability for retirement benefits	1,132	1,233	10,332
Loss on fixed assets	1,999	1,998	18,245
Loss on devaluation of investments in securities	568	372	5,184
Tax loss carryforwards	2,092	773	19,094
Depreciation	391	335	3,568
Other	1,093	1,408	9,976
Total deferred tax assets	9,078	8,113	82,858
Less valuation allowance for tax loss carryforwards	(2,016)	(667)	(18,400)
Less valuation allowance for total deductible temporary differences and others	(2,454)	(2,393)	(22,398)
Total valuation allowance	(4,470)	(3,060)	(40,799)
Offset by deferred tax liabilities	(3,808)	(4,113)	(34,757)
Net deferred tax assets	¥ 798	¥ 939	\$ 7,283
Deferred tax liabilities:			
Net unrealised holding gain on securities	¥ (3,473)	¥ (5,227)	\$ (31,699)
Reserve for special depreciation for tax purposes	(0)	(1)	(0)
Reserve for deferred gain on property for tax purposes	(2,704)	(2,416)	(24,680)
Deferred gains on hedges	(32)	(32)	(292)
Other	(1,784)	(1,535)	(16,283)
Total deferred tax liabilities	(7,995)	(9,212)	(72,973)
Offset by deferred tax assets	3,808	4,113	34,757
Net deferred tax liabilities	¥ (4,186)	¥ (5,098)	\$ (38,207)

Total valuation allowance increased by ¥1,410 million (\$12,869 thousand). The main reason for the increase is due to the increase in the valuation allowance for tax loss carryforwards of the Company's consolidated subsidiaries by ¥1,349 million (\$12,312 thousand).

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

21. Income Taxes (continued)

Tax loss carryforwards and the related deferred tax assets expire as follows:

At 31st December, 2019

	Due in 1 year or less	Due after 1 year through 2 years	Due after 2 years through 3 years	Due after 3 years through 4 years	Due after 4 years through 5 years	Due after 5 years	Total
	<i>(Millions of yen)</i>						
Tax loss carryforwards (Note (a))	¥ 11	¥ 55	¥ 121	¥ 152	¥ 180	¥ 1,571	¥ 2,092
Less valuation allowance for tax loss carryforwards	(11)	(54)	(120)	(150)	(163)	(1,515)	(2,016)
Net deferred tax assets related to tax loss carryforwards	¥ –	¥ 0	¥ 0	¥ 1	¥ 17	¥ 56	¥ 75
							(Note (b))
	Due in 1 year or less	Due after 1 year through 2 years	Due after 2 years through 3 years	Due after 3 years through 4 years	Due after 4 years through 5 years	Due after 5 years	Total
	<i>(Thousands of U.S. dollars)</i>						
Tax loss carryforwards (Note (a))	\$ 100	\$ 502	\$ 1,104	\$ 1,387	\$ 1,642	\$ 14,339	\$ 19,094
Less valuation allowance for tax loss carryforwards	(100)	(492)	(1,095)	(1,369)	(1,487)	(13,828)	(18,400)
Net deferred tax assets related to tax loss carryforwards	\$ –	\$ 0	\$ 0	\$ 9	\$ 155	\$ 511	\$ 684
							(Note (b))

Notes to Consolidated Financial Statements (continued)

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

22. Other Comprehensive Loss

Other comprehensive loss related to reclassification adjustments and tax effects allocated to each comprehensive loss for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are summarised as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Net unrealised holding loss on securities:			
Amount arising during the year	¥ (173)	¥ (1,006)	\$ (1,579)
Reclassification adjustments	(5,296)	(425)	(48,338)
Amount before income tax effect	(5,469)	(1,432)	(49,917)
Income tax effect	1,753	396	16,000
Total	(3,716)	(1,035)	(33,917)
Deferred gain on hedges:			
Amount arising during the year	15	200	136
Reclassification adjustments	(14)	(95)	(127)
Amount before income tax effect	1	105	9
Income tax effect	(0)	(32)	(0)
Total	0	73	0
Translation adjustments:			
Amount arising during the year	231	(1,435)	2,108
Retirement benefits liability adjustments:			
Amount arising during the year	360	(335)	3,285
Reclassification adjustments	45	(118)	410
Amount before income tax effect	405	(453)	3,696
Income tax effect	(124)	138	(1,131)
Total	281	(314)	2,564
Share of other comprehensive loss of affiliates accounted for by the equity method:			
Adjustments arising during the year	(153)	(184)	(1,396)
Total other comprehensive loss	¥ (3,354)	¥ (2,896)	\$ (30,613)

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

23. Investment and Rental Property

The Company and certain consolidated subsidiaries own rental office buildings, rental commercial facilities and others in Tokyo, Japan and other areas.

Rental revenues are recorded under “Rental income on real estate” and rental costs are recorded mainly under “Other, net” in the consolidated statement of income and comprehensive income for the nine months ended 31st December, 2019 and the year ended 31st March, 2019. Net rental income, net of rental cost, for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 was ¥364 million (\$3,322 thousand) and ¥507 million, respectively.

The carrying value in the consolidated balance sheet and corresponding fair value of investment and rental properties as of 31st December, 2019 and 31st March, 2019 are as follows:

	<i>Carrying value</i>			<i>Fair value</i>
	1st April, 2019	Net change	31st December, 2019	31st December, 2019
	<i>(Millions of yen)</i>			
Investment and rental property	¥ 12,444	¥ 302	¥ 12,746	¥ 18,940
	<i>Carrying value</i>			<i>Fair value</i>
	1st April, 2018	Net change	31st March, 2019	31st March, 2019
	<i>(Millions of yen)</i>			
Investment and rental property	¥ 12,764	¥ (319)	¥ 12,444	¥ 16,987
	<i>Carrying value</i>			<i>Fair value</i>
	1st April, 2019	Net change	31st December, 2019	31st December, 2019
	<i>(Thousands of U.S. dollars)</i>			
Investment and rental property	\$ 113,581	\$ 2,756	\$ 116,338	\$ 172,873

The carrying value represents the acquisition costs less accumulated depreciation and accumulated impairment loss.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

23. Investment and Rental Property (continued)

The main component of net change in the carrying value during the nine months ended 31st December, 2019 was the increase in the idle property of the Company's subsidiary liquidated during the nine months ended 31st December, 2019 in the amount of ¥358 million (\$3,267 thousand).

The main components of net change in the carrying value during the year ended 31st March, 2019 were the decrease due to sales of idle property in the amount of ¥279 million and the decrease due to depreciation in the amount of ¥26 million.

For major property, the fair value is determined based on the real-estate appraisal assessed by external real-estate appraisers. For other property, the fair value is determined based on the land price index issued by government authorities and others. However, unless the appraisal or indicators that are regarded to reflect the fair value of the property appropriately change significantly since the date of acquisition or the date of the latest appraisal, the Company and certain consolidated subsidiaries measure the fair value of the property based on such appraisal or indicators obtained previously and adjusted as appropriate.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information

Summary of reportable segments

The reportable segments of the Group are components for which discrete financial information is available and whose operating results are regularly reviewed by the Board of Directors to make decisions about resource allocation and to assess performance.

The Group has established its business headquarters to control the business divisions at the corporate office. Each division formulates comprehensive domestic and overseas strategies for its products and services and conducts business activities according to these strategies.

The Group classifies its businesses into five reportable segments: Confectioneries and Food Products Division, Ice Cream Division, Dairy Division, Food Ingredients Division, and Overseas Division.

The Confectioneries and Food Products Division mainly produces and sells chocolate, cookies, gum, curry roux, retort-packed food and others.

The Ice Cream Division mainly produces and sells ice cream and others.

The Dairy Division mainly produces and sells milk, dairy products, western-style fresh confectioneries, baby formula and others.

The Food Ingredients Division mainly produces and sells starch, food colouring and others.

The Overseas Division mainly produces and sells snacks, ice cream and others overseas.

Calculation methods of sales, income or loss, assets and other items by reportable segment

The accounting policies of the reportable segments are substantially the same as those described in the Note 2 “Summary of Significant Accounting Policies”, except for the valuation method of inventory and the depreciation method of property, plant and equipment. Certain inventories are valued at the amounts used in inter-segment sales transactions before application of lower of cost or net realisable value. Certain property, plant and equipment are depreciated using the straight-line method. Segment income is determined based on operating income. Inter-segment transactions are determined based on market prices.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Information on sales, income or loss, assets and other items by reportable segment

	Nine months ended 31st December, 2019					
	Reportable segments					
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Subtotal
	(Millions of yen)					
Sales, income or loss and assets by reportable segment:						
Net sales:						
Sales to third parties	¥ 71,789	¥ 73,353	¥67,032	¥ 8,314	¥ 53,200	¥ 273,690
Inter-segment sales and transfers	598	84	8	164	—	855
Total	¥ 72,388	¥ 73,437	¥67,040	¥ 8,479	¥ 53,200	¥ 274,546
Segment income	¥ 5,236	¥ 6,209	¥ 2,386	¥ 648	¥ 1,260	¥ 15,742
Segment assets	49,584	39,138	29,574	5,650	26,993	150,941
Other items:						
Depreciation and amortisation	2,742	3,062	1,213	105	1,583	8,707
Increase in property, plant and equipment and intangible assets	3,200	1,799	1,824	225	1,395	8,445
	Nine months ended 31st December, 2019					
	Others	Total	Adjustments and eliminations		Consolidated	
	(Millions of yen)					
Sales, income or loss and assets by reportable segment:						
Net sales:						
Sales to third parties	¥ 14,496	¥ 288,187	¥	—	¥ 288,187	
Inter-segment sales and transfers	4,531	5,386	(5,386)		—	
Total	¥ 19,028	¥ 293,574	¥ (5,386)		¥ 288,187	
Segment income	¥ 251	¥ 15,993	¥ (388)		¥ 15,605	
Segment assets	1,390	152,331	191,480		343,812	
Other items:						
Depreciation and amortisation	200	8,907	1,937		10,845	
Increase in property, plant and equipment and intangible assets	98	8,543	5,152		13,696	

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Information on sales, income or loss, assets and other items by reportable segment (continued)

	Year ended 31st March, 2019					
	Reportable segments					
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Subtotal
			(Millions of yen)			
Sales, income or loss and assets by reportable segment:						
Net sales:						
Sales to third parties	¥ 94,905	¥ 85,037	¥ 90,149	¥ 10,768	¥ 51,572	¥ 332,434
Inter-segment sales and transfers	965	120	177	204	1	1,469
Total	¥ 95,871	¥ 85,157	¥ 90,327	¥ 10,973	¥ 51,573	¥ 333,904
Segment income	¥ 6,134	¥ 6,864	¥ 2,821	¥ 915	¥ 1,409	¥ 18,145
Segment assets	48,685	42,911	28,687	5,996	29,377	155,657
Other items:						
Depreciation and amortisation	3,050	4,196	1,706	133	1,731	10,819
Increase in property, plant and equipment and intangible assets	6,584	5,131	1,386	156	1,981	15,240
					</	

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Information on sales, income or loss, assets and other items by reportable segment (continued)

	Nine months ended 31st December, 2019					
	Reportable segments					
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Subtotal
	(Thousands of U.S. dollars)					
Sales, income or loss and assets by reportable segment:						
Net sales:						
Sales to third parties	\$ 655,248	\$ 669,523	\$ 611,829	\$ 75,885	\$ 485,578	\$ 2,498,083
Inter-segment sales and transfers	5,458	766	73	1,496	–	7,803
Total	<u>\$ 660,715</u>	<u>\$ 670,290</u>	<u>\$ 611,902</u>	<u>\$ 77,391</u>	<u>\$ 485,578</u>	<u>\$ 2,505,896</u>
Segment income	\$ 47,791	\$ 56,672	\$ 21,778	\$ 5,914	\$ 11,500	\$ 143,683
Segment assets	452,573	357,228	269,934	51,569	246,376	1,377,701
Other items:						
Depreciation and amortisation	25,027	27,948	11,071	958	14,448	79,472
Increase in property, plant and equipment and intangible assets	29,207	16,420	16,648	2,053	12,732	77,081
	Nine months ended 31st December, 2019					
	Others	Total	Adjustments and eliminations		Consolidated	
		(Thousands of U.S. dollars)				
Sales, income or loss and assets by reportable segment:						
Net sales:						
Sales to third parties	\$ 132,311	\$ 2,630,403		\$ –		\$ 2,630,403
Inter-segment sales and transfers	41,356	49,160		(49,160)		–
Total	<u>\$ 173,676</u>	<u>\$ 2,679,572</u>		<u>\$ (49,160)</u>		<u>\$ 2,630,403</u>
Segment income	\$ 2,290	\$ 145,974		\$ (3,541)		\$ 142,433
Segment assets	12,687	1,390,388		1,747,718		3,138,116
Other items:						
Depreciation and amortisation	1,825	81,297		17,679		98,986
Increase in property, plant and equipment and intangible assets	894	77,975		47,024		125,009

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Information on sales, income or loss, assets and other items by reportable segment (continued)

“Others” are businesses not included in the reportable segments, which mainly include the Health Division, the Office Glico Division and the System Maintenance and Development Division.

The adjustments and eliminations for segment income in the amounts of ¥388 million (\$3,541 thousand) and ¥1,735 million consisted of the elimination of inter-segment transactions and other adjustments of ¥1,740 million (\$15,881 thousand) and ¥1,290 million and corporate expenses not allocated to each reportable segment of ¥2,128 million (\$19,423 thousand) and ¥3,026 million for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively.

Corporate expenses were mainly related to selling, general and administrative expenses not attributable to reportable segments for the nine months ended 31st December, 2019 and the year ended 31st March, 2019. The adjustments and eliminations for segment assets in the amount of ¥191,480 million (\$1,747,718 thousand) and ¥191,395 million at 31st December, 2019 and 31st March, 2019, respectively, consisted of corporate assets not attributable to reportable segments.

The adjustments and eliminations for depreciation and amortisation of ¥1,937 million (\$17,679 thousand) and ¥2,078 million and increase in property, plant and equipment and intangible assets of ¥5,152 million (\$47,024 thousand) and ¥7,172 million for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively, consisted of depreciation and amortisation and acquisition of corporate assets not attributable to reportable segments.

Segment income corresponds to operating income in the consolidated statement of income and comprehensive income.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Related information

Information by products and services

Sales to third parties categorised by products and services for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are summarised as follows:

Nine months ended 31st December, 2019						
Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
<i>(Millions of yen)</i>						
¥ 71,789	¥ 73,353	¥ 67,032	¥ 8,314	¥ 53,200	¥ 14,496	¥ 288,187
Year ended 31st March, 2019						
Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
<i>(Millions of yen)</i>						
¥ 94,905	¥ 85,037	¥ 90,149	¥ 10,768	¥ 51,572	¥ 17,836	¥ 350,270
Nine months ended 31st December, 2019						
Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
<i>(Thousands of U.S. dollars)</i>						
\$ 655,248	\$ 669,523	\$ 611,829	\$ 75,885	\$ 485,578	\$ 132,311	\$ 2,630,403

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Related information (continued)

Geographical information

(1) Net sales

Net sales categorised by countries and regions based on locations of customers of the Group for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 are summarised as follows:

Nine months ended 31st December, 2019				
Japan	China	Southeast Asia	Others	Total
		<i>(Millions of yen)</i>		
¥ 234,987	¥ 26,774	¥ 16,625	¥ 9,800	¥ 288,187
Year ended 31st March, 2019				
Japan	China	Southeast Asia	Others	Total
		<i>(Millions of yen)</i>		
¥ 298,698	¥ 27,215	¥ 15,053	¥ 9,303	¥ 350,270
Nine months ended 31st December, 2019				
Japan	China	Southeast Asia	Others	Total
		<i>(Thousands of U.S. dollars)</i>		
\$ 2,144,824	\$ 244,377	\$ 151,743	\$ 89,448	\$ 2,630,403

(2) Property, plant and equipment

Property, plant and equipment categorised by countries and regions as of 31st December, 2019 and 31st March, 2019 are summarised as follows:

31st December, 2019				
Japan	China	Southeast Asia	Others	Total
		<i>(Millions of yen)</i>		
¥ 87,875	¥ 5,886	¥ 5,265	¥ 779	¥ 99,807
31st March, 2019				
Japan	China	Southeast Asia	Others	Total
		<i>(Millions of yen)</i>		
¥ 86,910	¥ 5,881	¥ 5,839	¥ 834	¥ 99,465
31st December, 2019				
Japan	China	Southeast Asia	Others	Total
		<i>(Thousands of U.S. dollars)</i>		
\$ 802,071	\$ 53,723	\$ 48,055	\$ 7,110	\$ 910,980

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Related information (continued)

Information on loss on impairment of fixed assets

Nine months ended 31st December, 2019							
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
	<i>(Millions of yen)</i>						
Loss on impairment of fixed assets	¥ 10	¥ 102	¥ 3	¥ –	¥ 3,000	¥ 133	¥ 3,249
Year ended 31st March, 2019							
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
	<i>(Millions of yen)</i>						
Loss on impairment of fixed assets	¥ 12	¥ 0	¥ 33	¥ –	¥ 136	¥ 125	¥ 307
Nine months ended 31st December, 2019							
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
	<i>(Thousands of U.S. dollars)</i>						
Loss on impairment of fixed assets	\$ 91	\$ 930	\$ 27	\$ –	\$ 27,382	\$ 1,213	\$ 29,654

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

24. Segment Information (continued)

Related information (continued)

Information on amortisation of goodwill and remaining unamortised balance by reportable segment

Nine months ended 31st December, 2019							
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
	(Millions of yen)						
Amortisation for the year	¥ –	¥ –	¥ –	¥ –	¥ 433	¥ –	¥ 433
Remaining unamortised balance	¥ –	¥ –	¥ –	¥ –	¥ 489	¥ –	¥ 489
Year ended 31st March, 2019							
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
	(Millions of yen)						
Amortisation for the year	¥ –	¥ –	¥ –	¥ –	¥ 423	¥ –	¥ 423
Remaining unamortised balance	¥ –	¥ –	¥ –	¥ –	¥ 3,874	¥ –	¥ 3,874
Nine months ended 31st December, 2019							
	Confectioneries and Food Products	Ice Cream	Dairy	Food Ingredients	Overseas	Others	Total
	(Thousands of U.S. dollars)						
Amortisation for the year	\$ –	\$ –	\$ –	\$ –	\$ 3,952	\$ –	\$ 3,952
Remaining unamortised balance	\$ –	\$ –	\$ –	\$ –	\$ 4,463	\$ –	\$ 4,463

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

25. Amounts per Share

Amounts per share at 31st December, 2019 and 31st March, 2019 and for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 were as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Yen)</i>		<i>(U.S. dollars)</i>
Profit attributable to owners of the parent	¥ 185.31	¥ 180.02	\$ 1.69
Cash dividends	60.00	60.00	0.54
Net assets	3,284.19	3,250.07	29.97

Profit attributable to owners of the parent per share has been computed based on the profit available for distribution to shareholders of common stock and the weighted-average number of shares of common stock outstanding during each respective year. Net assets per share have been computed based on the net assets available for distribution to the shareholders of common stock and the number of shares of common stock outstanding at the balance sheet date.

The number of the Company's shares held by the E-Ship Trust of 16 thousand shares and 54 thousand shares at 31st December, 2019 and 31st March, 2019, respectively were excluded from the number of shares of common stock used in the computation of net assets per share.

The weighted-average number of the Company's shares held by the E-Ship Trust of 36 thousand shares and 72 thousand shares for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively, and that held by the BIP Trust of 10 thousand shares for the year ended 31st March, 2019, were excluded from the number of shares of common stock used in the computation of profit attributable to owners of the parent.

Diluted profit per share for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 has not been disclosed because no dilutive potential shares with dilutive effect existed for the nine months ended 31st December, 2019 and the year ended 31st March, 2019, respectively.

Cash dividends per share represent the cash dividends proposed by the Board of Directors as applicable to the respective fiscal period and year together with the interim cash dividends paid.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

25. Amounts per Share (continued)

The financial data used in the computation of profit attributable to owners of the parent per share for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 is summarised as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Profit attributable to owners of the parent	¥ 12,047	¥ 11,844	\$ 109,958
	Nine months ended 31st December, 2019	Year ended 31st March, 2019	
	<i>(Thousands of shares)</i>		
Weighted-average number of shares of common stock	65,013	65,795	

Descriptions of dilutive potential shares that were not included in the computation of diluted profit per share for the nine months ended 31st December, 2019 and the year ended 31st March, 2019 because of no dilutive effect are as follows:

	Nine months ended 31st December, 2019	Year ended 31st March, 2019	Nine months ended 31st December, 2019
	<i>(Millions of yen)</i>		<i>(Thousands of U.S. dollars)</i>
Euro-Yen denominated convertible bonds due 2024	¥ 30,000	¥ 30,000	\$ 273,822
	31st December, 2019	31st March, 2019	
	<i>(Shares)</i>		
Number of stock acquisition rights	3,000	3,000	

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

26. Significant Subsequent Event

The Company resolved at the Board of Directors' meeting on 18th March, 2020 that Glico Manufacturing Japan Co., Ltd., a newly established company will conduct an absorption-type merger with the Company's 14 domestic consolidated manufacturing subsidiaries effective 1st July, 2020 (expected date).

(1) Overview of the new company to be established

- | | |
|--------------------------|--|
| 1) Corporate name | Glico Manufacturing Japan Co., Ltd. |
| 2) Location | 6-5, Utajima 4-chome, Nishiyodogawa-ku, Osaka |
| 3) Representative | Koso Shiraishi |
| 4) Business description | Manufacturing and sales of confectioneries, food products, ice cream and dairy products |
| 5) Capital amount | ¥100 million (\$912 thousand) |
| 6) Date of establishment | 1st April, 2020 (succeeding the business of the Company's consolidated manufacturing subsidiaries by way of an absorption-type merger effective 1st July, 2020) (expected) |

(2) Outline of the merger

1) Names and business descriptions of the constituent companies

Surviving company in absorption-type merger

Name	Glico Manufacturing Japan Co., Ltd.
Business description	Refer to (1) above

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

26. Significant Subsequent Event (continued)

(2) Outline of the merger (continued)

1) Names and business descriptions of the constituent companies (continued)

Absorbed companies

Names	Kansai Glico Manufacturing Co., Ltd., Tottori Glico Manufacturing Co., Ltd., Kanto Glico Manufacturing Co., Ltd., Chiba Glico Manufacturing Co., Ltd., Mie Glico Manufacturing Co., Ltd., Hyogo Glico Manufacturing Co., Ltd., Ibaraki Glico Manufacturing Co., Ltd., Sendai Glico Manufacturing Co., Ltd., Tohoku Glico Manufacturing Co., Ltd., Nasu Glico Manufacturing Co., Ltd., Tokyo Glico Manufacturing Co., Ltd., Gifu Glico Manufacturing Co., Ltd., Saga Glico Manufacturing Co., Ltd., Glico Icreo Manufacturing Co., Ltd.
Business descriptions	Manufacturing and sales of confectioneries, food products, ice cream and dairy products

2) Date of the merger (effective date)

1st July, 2020

3) Legal form of the merger

The merger is an absorption-type merger where Glico Manufacturing Japan Co., Ltd. becomes the surviving company and the Company's domestic consolidated manufacturing subsidiaries become absorbed companies.

4) Shares and dividends to be allocated with the merger

Glico Manufacturing Japan Co., Ltd., the surviving company, and the Company's domestic consolidated manufacturing subsidiaries, the absorbed companies, are all wholly owned subsidiaries of the Company. No shares, cash or other assets dividends will be allocated for the merger.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

26. Significant Subsequent Event (continued)

(2) Outline of the merger (continued)

5) Purpose of the merger

The purpose of the merger is to improve quality of products by sharing technology and knowledge base, and to increase human resource capabilities and talent by restructuring the training structure, and to realise standardisation of business processes and to enhance productivity by integrating the back-offices by merging the Company's consolidated manufacturing subsidiaries, and optimise the production function within the group as a whole.

(3) Outline of the accounting treatment applied

The merger will be accounted for as a transaction under common control in accordance with "Accounting Standard for Business Combinations" (ASBJ Statement No. 21, issued on 13th September, 2013) and "Implementation Guidance on Accounting Standard for Business Combinations and Accounting Standard for Business Divestitures" (ASBJ Guidance No. 10, issued on 13th September, 2013).

(4) Future outlook

Glico Manufacturing Japan Co., Ltd. is a wholly owned manufacturing subsidiary of the Company. Its absorption-type merger with the domestic consolidated manufacturing subsidiaries will be, therefore, a merger among wholly owned subsidiaries of the Company, therefore, the impact on the Company's consolidated financial performance will be immaterial.

Ezaki Glico Co., Ltd. and Consolidated Subsidiaries

Notes to Consolidated Financial Statements (continued)

Corporate Information

Board of Directors and Statutory Auditors (as of 31st March, 2020)

President & CEO

Katsuhisa Ezaki

Standing Corporate Auditors

Toshiaki Yoshida

Akira Onuki

Senior Managing Executive Officer and
Representative Director

Etsuro Ezaki

Corporate Auditors

Shintaro Iwai

Matao Miyamoto

Minoru Kudo

Directors

Takashi Kuriki

Yutaka Honzawa

Tetsuo Masuda

Takatoshi Kato

Kanoko Oishi

George Hara

Corporate Data (as of 31st December, 2019)

Head Office

6-5, Utajima, 4-chome,
Nishiyodogawa-ku, Osaka 555-8502, Japan

Tel: (06)6477-8352

Fax: (06)6477-8250

Number of Employees

1,525

Stock Exchange Listing

Tokyo

Tokyo Branch

10-18, Takanawa, 4-chome, Minato-ku,
Tokyo 108-0074, Japan

Transfer Agents

Sumitomo Mitsui Trust Bank, Limited.
5-33, Kitahama, 4-chome, Chuo-ku,
Osaka 541-0041, Japan

Paid-in Capital

¥7,773 million

(U.S. \$70,947 thousand)

Established

1922
